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CHAPTER 1 
1. INTRODUCTION 
1.1 Importance and overview of microparticles for drug delivery 
Particles for drug delivery are widely researched for use as drug delivery devices due to 
several advantages over conventional drug tablets. Figure 1 shows an example graph that illustrates 
two key advantages of drug loaded particles for the consumer. Each curve shown in Figure 1 
illustrates an example blood drug concentration profile for one administered dose for either a 
conventional drug tablet or the optimal drug loaded particles. As shown in the Figure the 
conventional drug tablet requires three times more doses to get approximately the same effect as a 
single dose of the optimal drug loaded particles. Additionally, it is important to notice that the 
profile for the conventional tablet spikes to the side effects region and immediately decreases. 
Whereas the drug loaded particles result in a sustained blood drug concentration within the 
therapeutic region for an extended period of time. In summary, for the consumer, conventional 
drug tablets require more doses and can have side effects, whereas the optimal drug loaded 
particles allow you to reduce the number of doses and eliminate potential side effects, increasing 
patient comfort and compliance. 
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Figure 1. Example graph illustrating two key advantages for the optimal drug loaded particles 
over conventional drug tablets; conventional drug tablet (blue dotted line) and optimal particles 
for drug delivery (green line).  
 
In additional to these consumer advantages, for the manufacturer, the development of drug delivery 
devices is 100 times cheaper and take half the time to develop than a new drug.1  
Particle sizes typically fabricated for drug delivery applications are either in the nano or 
micron size range. However, the micron size range has several advantages over the nano size range. 
In particular, local and inhalation delivery are not easily targetable for nanoparticle drug delivery. 
For local delivery nanoparticles do not stay at the site of injection due to their small size, whereas 
microparticles of a large enough size do, such as 55 to 60 micron size particles for sciatic nerve 
block.2 For inhalation delivery nanoparticles are inhaled then exhaled3, whereas microparticles 
that are 1 to 2 microns in aerodynamic diameter achieve efficient distribution in the deep lungs.4 
Lastly, there is one crucial, but simple advantage of microparticles over nanoparticles. This is the 
fact that microparticles will always have a longer extended release than their corresponding 
nanoparticles, due to an increased diffusion path length and degradation time.  
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Several researchers have capitalized on the advantages previously stated. Figures 2 and 3 
show the variety of publications on microparticles used for different applications and routes of 
administration respectively. As shown in Figure 2 the most common diseases targeted for 
microparticles in drug delivery are cancer and diabetes. Furthermore, Figure 3 shows that the 
routes of administration that are most frequently published on are oral and inhalation. 
 
Figure 2. Percentage of publications on different diseases treated using drug loaded 
microparticles. The figure summarizes data that was extracted by Michael Anthony Marin from 
100+ publications mostly from 2010 to 2018. See the Appendix for tables containing detailed data 
from the summarized articles. 
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Figure 3. Percentage of publications on different routes of administration for drug loaded 
microparticles. The figure summarizes data that was extracted by Michael Anthony Marin from 
100+ publications mostly from 2010 to 2018. See the Appendix for tables containing detailed data 
from the summarized articles. 
 
1.2 Microparticle networks for drug encapsulation and delivery 
A key part in designing microparticles for a specific drug delivery application is 
microparticle network selection. In general, microparticle networks are formed by 
precipitation/physical entanglement, polymerization/covalent crosslinking, or ionic crosslinking. 
Figure 4 shows the percentage of publications on the different type of microparticle networks. As 
shown in Figure 4 the highest frequency of publications are on the preparation of microparticles 
composed of precipitation/physical entanglement networks. 
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Figure 4. Percentage of publications on different microparticle networks for drug delivery. The 
figure summarizes data that was extracted by Michael Anthony Marin from 100+ publications 
mostly from 2010 to 2018. See the Appendix for tables containing detailed data from the 
summarized articles. 
 
One significant difference between these three categories of networks is that 
polymerization/covalent crosslinked networks have a high degree of tunability and allow for a 
controlled and extended release of drug.5 These features are highly desirable and the work 
presented here is focused on the development of covalently crosslinked microparticles. 
1.3 Precision of microparticle fabrication methods 
Methods commonly used to fabricate microparticles include emulsion, spray drying, 
supercritical fluid, and microfluidics. Figure 5 shows the percentage of publications on each of the 
different methods used to prepare microparticles for drug delivery. This figure shows that emulsion 
and spray drying methods are the most common. 
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Figure 5. Percentage of publications on microparticle fabrication methods. The figure summarizes 
data that was extracted by Michael Anthony Marin from 100+ publications mostly from 2010 to 
2018. See the Appendix for tables containing detailed data from the summarized articles. 
 
In general, each microparticle fabrication method shown in Figure 4 fabricates microparticles with 
a characteristic coefficient of variation (CV) defined as; 
 coefficient	of	variation	(CV) = 1232          (1) 
 
where sd is the standard deviation for the microparticle diameter and ad is the average microparticle 
diameter. The CV value measures how well the method can prepare precisely sized microparticles. 
The higher the CV value, the less precise in size the fabricated microparticles are. A low CV value 
is very important to ensure consistent and predictable release kinetics. Low CV is also important 
for certain routes of administration such as inhalation, which require distinct particle sizes from 1 
to 15 microns to reach different locations within the lung.4 Table 1 shows a size range summary 
of microparticles fabricated utilizing each technique shown in Figure 5 and the typical coefficient 
of variation obtained.  
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Table 1. Size range and coefficient of variation of microparticles prepared utilizing different 
fabrication methods. The size range and coefficient of variation data was extracted by Michael 
Anthony Marin from 100+ publications mostly from 2010 to 2018. See the Appendix for tables 
containing detailed data from the summarized articles. 
Fabrication Method Size Range (µm) CV (%) 
Emulsion 1.0 to 95.0 42 ± 32 
Spray drying 1.7 to 10.0 59 ± 28 
Supercritical fluid 1.6 to 2.3 88 ± 13 
Microfluidics 2.0 to 142.1 10 ± 6 
 
As shown in Table 1 emulsion, spray drying, and supercritical fluid fabrication methods typically 
result in microparticles with high coefficient of variations averaging 42, 59, and 88% respectively. 
Whereas microfluidics fabricates microparticles with an average CV value of 10%, a much higher 
size precision. 
1.4 Drug loading and encapsulation efficiency obtained for microparticle fabrication 
methods 
 
Drug loading in microparticles is achieved by post soaking, covalent bonding of drug, or 
physical entrapment during network formation. In general, post soaking methods and covalent 
bonding of drug result in optimal encapsulation efficiency and high drug loading. However, post 
soaking methods are typically only used for biologicals and hydrophilic drugs. Post soaking 
methods are also limited to the use of polymers that swell in cold water and shrink above 37 °C. 
The swelling behavior of these polymers can result in unpredictable release profiles. Covalent 
bonding of drug is a specialized technique that requires complex chemistry and testing to ensure 
that the covalent bonds do not alter the activity of the therapeutic, and only release drug through 
degradation. The reasons mentioned here limit the drug loading tunability and the practicality of 
post soaking and covalent bonding drug loading. This work only focuses on methods that involve 
the physical entrapment of drugs, which is practical and results in a high level of tunability. 
The highest drug loading percentage and encapsulation efficiency for each method is 
shown in Tables 2, 3, and 4 for biologicals, synthetic hydrophilic drugs, and synthetic hydrophobic 
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drugs respectively. Table 2 shows that for biologicals the method that resulted in the highest 
loading was emulsion precipitation/physical entanglement, whereas a microfluidics method 
resulted in the highest encapsulation efficiency. Table 3 shows that for hydrophilic drug loading 
and encapsulation efficiency a spray drying precipitation method resulted in the highest values. 
Lastly, Table 4 shows that for hydrophobic drug loading a microfluidics precipitation method 
resulted in the highest encapsulation efficiency whereas a spray drying precipitation method 
resulted in the highest drug loading. In summary, there is not one method that is optimal for high 
drug loading and optimal encapsulation efficiency for synthetic hydrophilic, synthetic 
hydrophobic, and biological therapeutics. Additionally, there are only a few articles on dual 
loading as shown in Table A3 in the Appendix, and no articles on triple loading of drugs. 
Table 2. Drug loading and encapsulation efficiency for biologicals loaded by physical entrapment. 
The drug loading and encapsulation efficiency data was extracted by Michael Anthony Marin from 
100+ publications mostly from 2010 to 2018. See the Appendix for tables containing detailed data 
from the summarized articles. 
Fabrication Method Highest drug loading (%) R 
Highest encapsulation 
efficiency (%) R 
Emulsion Precipitation 22.1 6 90 6 
Emulsion Polymerization 1.9 7 36 8 
Spray Drying Precipitation 9.7 9 97 9 
Supercritical Precipitation 48 10 97 10 
Microfluidics Precipitation 5.9 11 99 11 
 
Table 3. Drug loading and encapsulation efficiency for hydrophilic loaded drugs by physical 
entrapment. The drug loading and encapsulation efficiency data was extracted by Michael Anthony 
Marin from 100+ publications mostly from 2010 to 2018. See the Appendix for tables containing 
detailed data from the summarized articles. 
Fabrication Method Highest drug loading (%) R 
Highest encapsulation 
efficiency (%) R 
Emulsion Ionic Crosslinking 13 12 66 12 
Emulsion Polymerization 0.4 8 7.6 8 
Spray Drying Precipitation 14 13 95 13 
Microfluidics Precipitation 1 14 30 14 
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Table 4. Drug loading and encapsulation efficiency for hydrophobic loaded drugs by physical 
entrapment. The drug loading and encapsulation efficiency data was extracted by Michael Anthony 
Marin from 100+ publications mostly from 2010 to 2018. See the Appendix for tables containing 
detailed data from the summarized articles. 
Fabrication Method Highest drug loading (%) R 
Highest encapsulation 
efficiency (%) R 
Emulsion Precipitation 20 15 93 16 
Spray Drying Precipitation 49 17 96 18 
Supercritical Precipitation 14 19 63 19 
Microfluidics Precipitation 30 20 97 21 
 
1.5 Development of a comprehensive technology to engineer tunable drug loaded 
microparticles 
 
 As summarized previously, a comprehensive method has not been invented that can easily 
fabricate tunable microparticles at a high rate with low CV, and have the ability to encapsulate 
synthetic hydrophilic, synthetic hydrophobic, and/or biologicals with a high drug loading and 
encapsulation efficiency. The goal of this work was to develop a comprehensive technology that 
can accomplish this. The approach to accomplish this goal was to first identify properties important 
in drug delivery such as release kinetics, route of administration, dose, type of drug loading 
(hydrophilic, hydrophobic, and/or biological), and microparticle circulation time. Microparticle 
properties were then identified that could tune these drug delivery properties. For example, the 
release kinetics can be tuned by the microparticle network density, the route of administration 
through the microparticle size, the type of drug loading (hydrophilic, hydrophobic, and/or 
biological) through the microparticle hydrophilic character, and the microparticle circulation time 
through the microparticle softness22. A goal was then set to tune the identified microparticle 
properties over a wide range thereby allowing us to engineer microparticles for a wide range of 
drug delivery applications. The strategy to accomplish this goal was to utilize piezoelectric ink jet 
printing, a method known to produce precisely sized droplets in the micron size range with tunable 
ejection volume, and development of a fundamental set of photoreactive monomer and copolymer 
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inks that allow us to tune the microparticle softness, hydrophilicity, and network density over a 
wide range. By innovatively selecting piezoelectric ink jet printing to fabricate microparticles we 
should be able to easily tune the microparticle size through the ejected droplet volume while 
maintaining high size precision, and also tune the drug loading while maintaining high 
encapsulation efficiency. The droplet volume can be tuned through the jetting waveform, nozzle 
temperature, and/or nozzle size while maintaining high size precision through properly tuned 
jetting. The drug loading can be tuned simply by changing the ink, and high encapsulation 
efficiency should be achieved because the droplets are rapidly crosslinked after printing 
encapsulating the drug within. Surprisingly, no one has published on the use piezoelectric ink jet 
printing to fabricate drug loaded microparticles. By printing photoreactive inks we can covalently 
crosslink the printed droplets after printing using UV or visible light, physically encapsulating the 
drug within the covalently crosslinked microparticle networks. The microparticles could then be 
collected by washing or by dissolving the substrate depending on the microparticle-substrate 
interaction. With the fabrication method now selected we just had to develop a small set of 
photoreactive inks that allow us to obtain microparticles with a wide range of softness, 
hydrophilicity, and network density. We hypothesized that by strategically incorporating ink 
network precursors composed of reactive copolymer and crosslinker combinations (different 
structure and molecular weight) or photoreactive crosslinking monomers, we could tune the 
softness, hydrophilicity, and network density over a wide range. To ensure that a minimum amount 
of inks were needed we exploited the structure-property relationship boundaries of these 
copolymer and monomer network precursors. This was done by synthesizing a functionalized 
hydrophilic semibranched copolymer and hydrophobic linear copolymer with varying amounts of 
functionality, and the utilization of a crosslinking monomer. The functionalized copolymers were 
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synthesized to contain allyl groups that can react with dithiol crosslinkers to form the microparticle 
network. By preparing mixtures of these two copolymers we sought to obtain a wide range of 
microparticle hydrophilicity. Tunable softness and network density was obtained by changing the 
dithiol crosslinker length or by changing the % of allyl group incorporation. The developed 
photoreactive copolymer inks allow for fabrication of microparticles with a wide range of 
properties. However, in case fully crosslinked microparticle networks are needed for extreme 
extended release applications, we developed an ink composed of 100% reactive precursor network 
components through the incorporation of a tri-functionalized crosslinking monomer. Through this 
fundamental set of copolymer and monomer network precursors and strategic selection of other 
ink components, we developed four photoreactive inks that can fabricate a wide range of 
microparticles for a wide range of drug delivery applications. 
1.6 Testing of the developed comprehensive technology 
Microparticles were fabricated using each of the four developed inks. To facilitate 
microparticle characterization, a dye was incorporated into each ink formulation to allow for 
microparticle visualization using fluorescent microscopy. Microparticle-laden substrates were 
characterized using wide field microscopy to investigate the droplet placement on the substrate. 
Whereas confocal microscopy was utilized to investigate the microparticle shape, dye 
distribution throughout the microparticle, and microparticle size precision. We then sought to 
verify our predicted structure-property relationships. This was accomplished by designing and 
implementing efficient experiments to test the softness through unconfined compression testing, 
hydrophilicity through swelling studies, and size tuning using confocal microscopy. After 
verification of tunable properties we utilized the developed technology to fabricate optimal 
microparticles for a high impact drug delivery application, malaria elimination.  
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Malaria is a disease most prominent in sub-Saharan Africa where 80% of the global 
burden is present. Without proper treatment severe complications and death is inevitable.23 In 
2016, 216 million cases of the disease were reported in 91 countries, an increase of 5 million 
cases since 2015. As mentioned in the World Health Organization (WHO) 2017 World Malaria 
Report, if new interventions are not developed for malaria treatment, then cases and death will 
almost certainly increase.24 
 Malaria elimination is a very challenging disease to eliminate since it is easily and rapidly 
transferred through mosquitos. Currently the primary malaria prevention is an insecticide-treated 
mosquito net which is implemented for over 54% of people at risk. Other strategies include 
employing rapid diagnostic tests (RDT) to determine if a patient is positive for the infection, then 
giving antimalarial drugs via oral administration for treatment. However, as indicated by the 
WHO report these therapeutic strategies are insignificant, and will likely not result in malaria 
elimination. A promising alternative strategy is mass drug administration (MDA). MDA 
eliminates the need for rapid diagnostic testing and mosquito nets and would ensure that the 
entire population is under treatment, proactively preventing infection from developing, 
eliminating malaria. 
 Mass drug administration is commonly executed using oral administration of 
therapeutics. However, the bioavailability of orally administered drugs is very low, due to the 
brief transit time in the gastric intestinal (GI) tract typically from 8 to 12 hours.25 A promising 
strategy to significantly improve the bioavailability of common orally administered therapeutics 
is to develop an extended release drug delivery device. One therapeutic that would be very 
effective when delivered using an extended release device is ivermectin. This drug can function 
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as a systematic insecticide which kills the mosquito after the mosquito sucks blood containing an 
ivermectin concentration of at least 8 ng/mL.26 
 The development of a drug delivery device for extended ivermectin delivery would make 
a significant step toward the elimination of malaria. In terms of feasible routes of administration 
for MDA therapeutics; oral, nasal, and inhalation are most attractive due to their non-invasive 
nature. Oral therapeutics however are exposed to a very acidic environment that can result in 
aggressive degradation of polymer drug delivery devices. Nasal administration has mucociliary 
clearance mechanisms that are hard to overcome. On the other hand, inhalation administration, 
with the properly engineered devices, can result in a successful extended release of drug via 
pulmonary drug delivery. Properties that would be essential to the success of these devices 
include 1) an aerodynamic diameter of 1 to 2 microns for efficient distribution in the deep lungs4, 
2) high drug loading of hydrophobic drug (ivermectin), and 3) a dense crosslinked network that 
results in an extended drug release. 
 Our fabrication strategy to engineer these microparticles for malaria elimination was to 
use our invented piezoelectric ink jet printing technology and the photoreactive monomer ink. 
Advantages of our technology include precise microparticle fabrication in the low micron size 
range which should result in microparticles with efficient lung distribution and consistent release 
kinetics. Furthermore, the photoreactive monomer ink was chosen since it is fundamentally 
composed of 100% of photoreactive hydrophobic monomers which should result in the highest 
density crosslinked network with the longest extended release of drug, and high drug loading due 
to the hydrophobic environment being very favorable for the hydrophobic drug ivermectin. 
 After fabrication the microparticles were evaluated solely using microparticle 
characterization and in vitro experiments that investigate the ivermectin loaded microparticle 
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transport steps from the time of inhalation, to the time of elimination. The transport steps 
encountered include; 1) the ivermectin loaded microparticle transport from the mouth to the deep 
lungs, 2) ivermectin transport from the microparticle to the lung epithelial layer, 3) ivermectin 
transport through the lung epithelial layer into the systematic circulation, 4a) ivermectin 
transport throughout the body and elimination from the body, and 4b) microparticle 
degradation/elimination from the body. Step 1 was not investigated via in vitro studies since it is 
well known to be governed by the aerodynamic particle size of 1 to 2 microns.4 Step 2 was first 
evaluated using in vitro release studies. Steps 2 and 3 were then simultaneously investigated 
utilizing an in vitro lung model and an in vitro-in vivo lung absorption correlation. Step 4a was 
not investigated since ivermectin is well known to have an elimination half-life of 18 hours once 
in the plasma.27 Lastly, step 4b was investigated using in vitro degradation studies at conditions 
relevant to those found in the deep lungs. 
 Microparticles were fabricated with 13 wt% of ivermectin with an aerodynamic diameter 
of 1.6 ± 0.7 microns, resulting in a high hydrophobic drug loading and the optimal size for efficient 
drug distribution in the deep lungs. In vitro release experiments show that the ivermectin release 
can be tuned through the monomer concentration. Through the in vitro lung permeability studies 
and an in vitro-in vivo drug absorption correlation we determined that ivermectin lung absorption 
should occur in vivo over approximately 21 days. Lastly, in vitro degradation studies showed that 
the degradation rate can be tuned by the monomer concentration. The results show promise that 
the fabricated microparticles will make a significant step towards malaria elimination via 
pulmonary drug delivery, but also demonstrate the potential of the developed comprehensive 
technology. 
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CHAPTER 2 
2. MATERIALS AND METHODS 
2.1 Materials 
All reaction solvents used were HPLC quality and purchased from Sigma Aldrich. All 
NMR solvents were purchased from Cambridge Isotope Laboratories, Inc. 2,2-
bis(hydroxymethyl) propionic acid (Bis-HPA), Amberlyst® 15 Hydrogen Form (A-15), allyl 
glycidyl ether (AGE), ³ 99%, sodium hydroxide, ³97%, anhydrous isoamyl alcohol (IAOH), 
3,6-Dioxa-1,8-octanedithiol, nile red, coumarin 30, and 2,2-dimethoxy-2-phenylacetophenone 
(DMPA) were purchased from Sigma Aldrich. A sulfo-cyanine3 carboxylic acid dye was 
purchased from Lumiprobe Corporation. Glycidol (GLY), 96% was purchased from Sigma 
Aldrich and vacuum distilled prior to use with a Kugelrohr short-path distillation device. 
Dulbecco’s Phosphate Buffered Saline (PBS), no calcium, no magnesium, was purchased from 
Life Technologies and the pH was optimized using either sodium hydroxide or hydrochloric acid 
prior to use. Poly(methyl methacrylate) and poly(ethylene glycol) calibration kits were purchased 
from Agilent Technologies. Thiol PEG dithiol (HS-PEG-SH) (1,500 g/mol) was purchased from 
Nanocs. 2,2'-Azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044) was purchased 
from Wako chemicals. Tin(II) trifuoromethane sulfonate, Sn(OTf)2 was purchased from Strem 
Chemicals Inc. Teflon sheets were obtained from ePlastics. Dialysis membranes (Spectra/Por® 
7, molecular weight cut-off (MSCO) : 1,000 Da) were obtained from Spectrum Laboratories, Inc. 
5-methyl-5-allyloxycarbonyl-1,3-dioxane-2-one (MAC), and 5-methyl-5-ethyloxycarbonyl-1,3-
dioxane-2-one (MEC) were synthesized according to the literature and recrystallized prior to 
use.28-29 All reaction solvents were HPLC quality and purchased from Sigma Aldrich. 
Triethylamine, eosin Y, ivermectin, dimethyl sulfoxide, ascorbic acid, and trimethylolpropane 
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triacrylate (technical grade, contains 600 ppm monomethyl ether hydroquinone as inhibitor), 
inhibitor remover (replacement packing for removing hydroquinone and monomethyl ether 
hydroquinone), cobalt chloride, hydrogen peroxide (50%), penicillin-streptomycin solution 
stabilized with 10,000 units penicillin and 10 mg streptomycin/mL (sterile-filtered, BioReagent, 
suitable for cell culture), hydrocortisone solution (50 µM, sterile-filtered, BioXtra, suitable for 
cell culture), sodium selenite (BioReagent, suitable for cell culture ³98%), transferrin human 
(powder, BioReagent, suitable for cell culture), retinoic acid (³98%, HPLC, powder), insulin 
human (recombinant, expressed in yeast (proprietary host)), dimethyl sulfoxide (for molecular 
biology), ethanolamine (liquid, BioReagent, suitable for cell culture, ³ 98%), TWEENÒ 80 
(viscous liquid), and ivermectin were purchased from Sigma Aldrich. Polyvinyl alcohol film was 
purchased from Tianjin Teda Ganghua Trade Co., LTD (China). Invitrogenä Molecular 
Probesä Vybrantä MTT cell proliferation assay kits, Corningä Transwellä multiple well plate 
with permeable polycarbonate membrane inserts, Gibcoä trypsin-EDTA (0.25%) phenol red, 
Gibcoä trypan blue solution (0.4%), Gibcoä Ham’s F-12K (Kaighn’s) medium, Gibcoä fetal 
bovine serum, Certified One Shotä, US origin, Gibcoä DMEM/F-12, o-phosphoethanolamine 
(MP Biomedicalsä), Forskolin from Coleus forskohlii (MP Biomedicalsä), bovine pituitary 
extract BT-215 Alfa Aesarä, and Gibcoä phosphate buffered saline solution pH 7.4 were 
purchased from Fischer Scientific. 
2.2 Synthesis of novel functionalized copolymers for microparticle fabrication 
2.2.1 Synthesis and characterization of hydrophobic linear poly(carbonate) copolymers 
Gel permeation chromatography (GPC) was carried out with a Waters chromatograph 
system equipped with a Waters 2414 refractive index detector, a Waters 2481 dual λ absorbance 
detector, a Waters 1525 binary HPLC pump, and four 5 mm Waters columns (300 mm x 7.7 
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mm) connected in series with increasing pore size (100, 1000, 100,000 and 1,000,000 Ǻ 
respectively). All runs were performed using dimethylformamide (DMF) with lithium bromide 
(LiBr) (1 mg/mL) and poly(styrene) standards. 
To prepare methyl ethyl carbonate/methyl allyl carbonate (MEC/MAC) copolymers a 25 
mL round bottom flask equipped with a stir bar was capped with a rubber septum then flame dried 
under nitrogen. Sn(OTf)2 (14mg; 33.6 µmol; 4 eq) was then added to the round bottom flask and 
the reaction vessel was immediately purged with nitrogen prior to the addition of isoamyl alcohol 
(IAOH) (37 mg; 2.42 mmol; 50 eq) via microsyringe. The initiator-catalyst mixture was then 
allowed to stir at room temperature for 30 minutes before the addition of the MEC and MAC 
monomers. The reaction flask was then submerged in an 80 °C oil bath and the reaction was 
allowed to proceed until stirring was impeded. The resulting polymer product was dialyzed against 
dichloromethane (DCM) in tubing with a molecular weight cut-off (MWCO) of 1 kDa for 3 days 
with 5 solvent changes. The pure MEC/MAC copolymer product was collected and dried using a 
rotovap then a high-pressure pump (80% yield). The PDI was determined as 1.1. 
2.2.2 Synthesis and characterization of hydrophilic semibranched poly(glycidol) copolymers 
Gel permeation chromatography (GPC) was carried out with a Waters chromatograph 
system equipped with a Waters 2414 refractive index detector, a Waters 2481 dual λ absorbance 
detector, a Waters 1525 binary HPLC pump, and four 5 mm Waters columns (300 mm x 7.7 
mm), connected in series with increasing pore size (100, 1000, 100,000 and 1,000,000 Ǻ 
respectively). All runs were performed using dimethylformamide (DMF) with LiBr (1 mg/mL) 
and polyethylene glycol standards. 
To prepare the metal catalyzed semibranched glycidol/allyl glycidyl ether (GLY/AGE) 
copolymers a 25 mL round bottom flask (RBF) equipped with stir bar was capped with a rubber 
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septum then flame dried under nitrogen. Sn(OTf)2 (5.2 mg; 12.48 µmol; 0.4 eq) was then added to 
the round bottom flask and the reaction vessel was then immediately purged with nitrogen prior to 
the addition of isoamyl alcohol (43.7 mg 495.6 µmol; 17.4 eq) via microsyringe. The initiator-
catalyst mixture was then allowed to stir at room temperature for 30 minutes before lowering the 
reaction vessel into an ice water bath. After the reaction vessel had been cooled for 5 minutes the 
AGE monomer (834 mg; 7.31 mmol; 250 eq) was added drop wise to the stirring reaction. The 
GLY monomer (2.17 g; 29.24 mmol; 1000 eq) was then added drop wise in 4 separate aliquots, 
allowing 5 minute breaks between each aliquot. This ensured the exothermic reaction did not 
overheat and decompose the components. After stirring was impeded (~14 hours) the crude 
reaction mixture was solubilized in a minimal amount of methanol and precipitated into vigorously 
stirring ethyl acetate. The precipitation solvent was then allowed to settle before carefully 
decanting the ethyl acetate. The resulting GLY/AGE copolymer was solubilized in methanol, 
removed to a weighed 6-dram vial, dried using a rotavap then a high vacuum pump to afford the 
translucent viscous product with a 75% yield. The PDI was determined as 1.6 with a Mw and Mn 
values of 7,480 g/mol and 4,622 g/mol respectively. The Sn(OTf)2 GLY homopolymers were 
synthesized by first flame drying and nitrogen purging a 25 mL round bottom flask (RBF) 
equipped with a stir bar and septum. The catalyst Sn(OTf)2 (5.4 mg, 0.013 mmol) was then added 
and the RBF was purged with nitrogen again. The initiator 3-methyl-1-butanol (54.48 µL, 0.5 
mmol) was added and the RBF was stirred for 30 minutes at room temperature then cooled to 0 
ºC. Glycidol (2.7 mL, 40.5 mmol) was added to the round bottom flask drop wise ¼ at a time in 5 
minute intervals. The reaction was then left to stir overnight at room temperature. For purification, 
the crude product was precipitated in room temperature ethyl acetate, then collected using 
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methanol and dried using a rotovap then a high-pressure pump to afford the purified product with 
94% yield. 
2.2.3 Green synthesis and characterization of hydrophilic semibranched poly(glycidol) 
copolymers 
 
1H and 13C NMR spectrum were obtained using a Bruker 600 spectrometer operating at 
600 and 150 MHz, respectively. The instrument was equipped with a 14.1 Tesla Bruker magnet, 
which was controlled by a Bruker AV-II console, and a 5mm Z-gradient TCI Cryo-probe. A 10 
second recycle delay was used to insure full relaxation between pulses, allowing for quantitative 
measurements. This data was then used to assign individual monomer peaks specific to the ring 
opening structure, thus allowing for the calculation of the polymer degree of branching and relative 
abundance of repeat units. 
Gel permeation chromatography (GPC, Agilent 1260 GPC/SEC system) was used to 
determine molecular weight and polydispersity (Mw/Mn, PDI) of the poly(glycidol) polymers. 
Dimethylformamide (DMF) containing 0.1% LiBr at 60 °C was used as the mobile phase 
through three serial Tosoh Biosciences TSKGel Alpha columns (Tokyo, Japan). A Shimadzu 
RID-10A refractive index detector and a Wyatt miniDAWN Treos multi-angle light scattering 
detector were used to calculate absolute molecular weight based on dh/dC values. The dh/dC 
values were experimentally determined by measuring the refractive index of serial dilutions of 
each polymer in the GPC mobile phase with an Abbemat 300 digital refractometer (Anton Paar). 
All GPC data was analyzed using ASTRA V software (Wyatt Technology). GPC derived 
polymer Mn values were calculated by comparison to poly(methyl methacrylate) (PMMA) 
standards (PMMA Calibration Kit, Agilent Technologies) and poly(ethylene glycol) standards 
(PEG Calibration Kit, Agilent Technologies). Briefly, a series of PMMA standards of known Mn 
were analyzed by GPC and quadratic regression analysis was performed to determine Mn as a 
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function of peak elution time. Mw and corresponding polydispersity (PDI) values were 
determined with Astra V software (Wyatt Technologies). 
Matrix assisted laser desorption/ionization-time of flight-mass spectroscopy (MALDI-
Tof-MS) measurements were performed using a Voyager DE-STR MS in reflector mode 
equipped with a nitrogen gas laser of wavelength 337 nm utilizing external calibration. The 
instrument parameters were set to 25,000 V, 90% grid, 600ns delay, and 1000 shots per 
spectrum. The poly(glycidol) based samples were formed using solutions of 10 mg polymer/mL 
water and saturated dithranol matrix solution in 2:1 water/acetonitrile. 
The green glycidol/allyl glycidyl ether (GLY/AGE) 70/30 copolymers were prepared by 
first adding glycidol monomer (17.5mmol, 2.3 eq) to a flame dried 25mL RBF equipped with a 
stir bar. The allyl glycidyl ether monomer (7.5mmol, 1.0 eq) was then added via syringe and the 
reaction vessel was lowered into an oil bath at 80 °C before the addition of Dulbecco’s Phosphate 
Buffer Saline (DPBS) (0.25mL; pH= 6.0). The reaction was then allowed to run for 72 hours before 
the crude product was removed from the oil bath, dissolved in a minimal amount of methanol, and 
precipitated into vigorously stirring ethyl acetate. After allowing the solution to settle, the 
supernatant was decanted and the resulting copolymer product was collected in methanol, 
transferred to a 6-dram vial, and dried using a rotovap then a high-pressure pump resulting in a 
yield of 40%.  
The green GLY homopolymers were prepared by first adding glycidol monomer (33mmol, 
1.0eq) to a flame dried 25 mL round bottom flask (RBF). The reaction vessels were then lowered 
into oil baths of varying temperature (60°C, 80°C, or 100°C) to ensure consistent reaction 
temperatures, followed by the addition of DPBS (0.25mL; pH= 6.0) to reach a concentration of 
13.5 mM. After 72 hours, the crude viscous polymer product was dissolved in a minimal amount 
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of methanol and precipitated into vigorously stirring acetone. The resulting solution was decanted 
to afford the pure GLY product as a translucent viscous material. The product was collected in 
methanol, transferred to a massed 6-dram vial, and dried using a rotovap and a high-pressure pump 
resulting in a yield of 31.8% and a PDI of 1.1. Table 5 shows the Mn and Mw values as determined 
using poly(methyl methacrylate), poly(ethylene glycol), and poly(styrene) standards.  
Table 5. Mean and weight average molecular weights for semibranched poly(glycidol) 
homopolymers determined using gel permeation chromatography with poly(methyl 
methacrylate), poly(ethylene glycol), and poly(styrene) standards. 
Standards Mn (g/mol) Mw (g/mol) 
poly(methyl methacrylate) 1101 1156 
poly(ethylene glycol) 1253 1316 
poly(styrene) 10380 10800 
 
2.3 Microparticle fabrication using photoreactive copolymer inks and piezoelectric ink jet 
printing 
 
Three photoreactive copolymer inks were prepared to fabricate microparticles with a wide 
range of softness, hydrophilicity, and network density. In a general procedure for the 
poly(carbonate) ink (PC Ink) and the poly(carbonate)-poly(glycidol) ink (PC:PG - 70:30 Ink), the 
allyl functionalized copolymers, poly(MEC MAC) and poly(GLY AGE) were solubilized in 
dimethyl sulfoxide (DMSO) before the addition of the 2,2-Dimethyoxy-2-phenylacetophenone 
(DMPA) photoinitiator calculated for 0.2 eq per alkene. After manual mechanical mixing, the 
dithiol 3,6-Dioxa-1,8-octanedithiol (0.5 eq per alkene) was added via syringe to the solution and 
mixed to form a homogenous solution. The addition order for the various ink components was 
varied for the PG Ink. For this ink we first dissolved the poly(GLY AGE) and solid dithiol-PEG 
(1.5 kDa), 0.5 eq per alkene, in half of the desired amount of water until completely dissolved, 
followed by the second half of water containing the water soluble photoinitiator (VA-44). The 
exact percentile of allyl functionality incorporation was determined using 1H-NMR spectroscopy. 
If the molecular weight is unknown or cannot be exactly determined, the molecular weight of the 
	 22	
repetition unit containing the allyl functionality (AGE) or (MAC) can be used to determine the 
quantity of the allyl groups of the sample. This quantity can then be utilized to calculate the exact 
amount of the initiator and crosslinker needed in the stated equivalents. 
The PC Ink was used to fabricate poly(carbonate) microparticles. In a more exact procedure 
the PC Ink was prepared as follows. Considering poly(MEC MAC) copolymers with a R.U. = 
952.2 g/mol and a 20% MAC unit incorporation. First, 9.57 mg (8.55 µL) which equals 52.5 µmol 
of 3,6-Dioxa-1,8-octanedithiol (182.3 g/mol, 0.5 eq. per alkene) was added via micro syringe to a 
solution of 100 mg poly(MEC MAC), 2,2,-dimethoxy-2-phenylacetophenone (DMPA, 0.2 eq. per 
alkene, stock solution), and 1 mg of nile red in 200 µL DMSO. 
The PG Ink was used to fabricate poly(glycidol) microparticles which was prepared as 
follows. Considering poly(GLY AGE) copolymers with a R.U. 410.5 g/mol and 20% of AGE unit 
incorporation.  First, 182.7 mg = 121.8 µmol of HS-PEG-SH (1,500 g/mol, 0.5 eq. per alkene) was 
dissolved in 0.5 mL distilled water together with 100 mg poly(GLY AGE). A second solution of 
0.5 mL distilled water and 15.74 mg = 48.72 µmol 2,2’-Azobis[2-(2-imidazolin-2-yl)propane] 
dihydrochloride (VA-044, 0.2 eq. per alkene) and <1 mg water-soluble sulfo-cyanine carboxylic 
acid Cy3 dye was then added to the first solution and mixed. 
The PC:PG Ink was used to fabricate poly(carbonate)-poly(glycidol) microparticles. Since 
this ink was prepared with PC and PG at a weight ratio of 30:70 this ink will be abbreviated as 
PC:PG (70:30) Ink. The procedure is as follows when considering poly(MEC MAC) copolymers 
with a R.U. = 952.2 g/mol that have a 20% MAC unit incorporation and poly(AGE GLY) 
copolymers with a R.U. 410.5 g/mol with 20% AGE unit incorporation. First, 11.94 µL (13.36 mg, 
73.3 µmol) 3,6-Dioxa-1,8-octanedithiol (182.3 g/mol, 0.5 eq. per alkene) was added via micro 
syringe to a solution of 70 mg poly(MEC MAC), 2,2-dimethoxy-2-phenylacetophenone (DMPA, 
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0.2 eq. per alkene, stock solution), 30 mg poly(GLY AGE) copolymer. and 1 mg of coumarin 30 
in 400 µL DMSO. 
After the ink was prepared, it was injected into a printer cartridge (Dimatix Materials 
Cartridge Model # DMC-11601/PN 700-10701-01) using a glass pipet. Both ink compositions that 
used DMSO as the solvent and contained hydrophobic network precursors (PC Ink and PC:PG 
(70:30)) were printed on glass slides coated with a sacrificial water-soluble poly(glycidol) coating. 
The poly(glycidol) was prepared as previously reported.30 The glass slides were prepared by spin-
coating with a sacrificial poly(glycidol) solution utilizing a Laurell Technologies Corporation, 
Model WS-400A-6NPP/LITE spin-coater. Before spin coating, each glass slide was cleaned using 
compressed nitrogen. The glass slide was then placed onto the spin-coater platform and the spin-
coater was set to 3500 rpm with a spin time of 25 seconds. Immediately after the spinning was 
started 10 to 15 drops of a 1 g of poly(glycidol) in 1 g of methanol solution were added using a 
glass pipet. The coated slides were then allowed to air dry overnight. For the ink using water as a 
solvent and the hydrophilic network precursors (PG Ink) Teflon sheets were used as printing 
substrates.  
Once the printer cartridge and appropriate substrates were prepared, the cartridge was 
inserted into the printer and the substrates were loaded onto the printer platform. The printer 
cartridge was then set to 37 °C and the recommended manufacturer’s waveform was chosen and 
set to have a maximum voltage of 40 V as shown in Figure 6.  
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Figure 6. Multistep pulse waveform with a maximum voltage of 40 V used to eject one set of 
droplets from the printer cartridge nozzles. 
 
The spacing between the printed droplets was then set for placement 100 microns apart from center 
to center in rows and columns on the 12” x 8” platform. After printing, the microparticles were 
illuminated with long wave UV light to initiate the crosslinking.  
2.3.1 Characterization 
Gelation kinetic studies were performed to determine the effect of molecular weight and 
concentration on copolymer gelation at constant concentration and molecular weight respectively. 
The model copolymers investigated were poly(carbonate) copolymers with 20% of allyl 
incorporation. For the constant molecular weight experiments the concentration was kept at 17.9 
wt%. Whereas for the constant concentration experiments the molecular weight was kept at 6802 
± 35 g/mol. The solution was prepared in a glass vial using the same procedure as the PC Ink. 
Once prepared, the solutions were illuminated with long wave UV until gelation occurred. The 
gelation time was recorded as the time when the solution did not move upon vial inversion. 
Fluorescent microscopy was used to investigate the size of fabricated microparticles and 
the microparticle-laden substrate. A Nikon AZ 100M wide field microscope equipped with a 5x 
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Plan Fluor was used to image the microparticles printed on the substrates. Excitation wavelengths 
were varied based upon the dye encapsulated within each particle. Microparticles containing nile 
red were irradiated with 543 nm light, while 488 nm was utilized for the coumarin 30 encapsulated 
microparticles, and 633 nm for the Sulfo-Cy7 encapsulated microparticles. The substrates were 
then washed with water in order to transfer the microparticles into confocal dishes for imaging on 
a Zeiss LSM 510 inverted confocal microscope to investigate the microparticle size precision, dye 
distribution throughout the microparticle, and the microparticle shape. The same wavelengths were 
utilized for the confocal microscope but with a 10x Plan Neofluar lens for wide field imaging to 
determine microparticle uniformity and a 63x Plan-APOCHROMAT OIL lens was used for 
investigation of single microparticles. 
Mechanical testing was used on the hydrogel samples to investigate softness. The hydrogel 
samples were prepared using ink preparation procedures previously described. The resulting 
hydrogel products were tested in triplicate. For the mechanical testing a rate of 1 mm/min was 
utilized on an Instron 5944. The compressive modulus was determined using the initial linear 
region for each sample on the stress versus strain curves. 
The hydrophilicity of bulk hydrogels was investigated using swelling studies. Bulk 
hydrogels were prepared using the ink preparation procedures as stated previously. Once the 
respective hydrogel was formed, the gels were then rinsed sequentially with 3 mL aliquots of 
water, methanol, methylene chloride, methanol and water again to remove any unreacted starting 
materials. The hydrogels were then freeze dried and weighed before commencing the swelling 
studies. The gel swelling was investigated by first soaking the gels in deionized water for 24 hours. 
Swelling measurements were then taken by gently blotting the gels dry before recording the 
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swelled mass. The percent water content post-swelling was quantified using the following 
equation: 
	 4567489:489: ×100%       (2) 
where Msw is the mass of the swelled hydrogel and Mdry is the weight of the dried gel. 
2.4 Microparticle fabrication using photoreactive monomer inks and piezoelectric ink jet 
printing 
Photoreactive monomer inks were developed to yield microparticles with low softness, 
high network density, and low hydrophilicity. The reactive monomer used for the ink was 
trimethylolpropane triacrylate, which polymerized via free radical polymerization to form 
crosslinked poly(acrylate) (PA) microparticles. Prior to ink preparation eosin Y (EY) stock 
solution was prepared in dimethyl sulfoxide (DMSO) (7.3 mg EY/mL DMSO). The 
trimethylolpropane triacrylate (TMPTA) monomer was purified by pipetting the pure monomer 
into the top of a 5 3/4" glass pipet filled with 80% inhibitor remover. Initially the liquid is 
allowed to flow from gravity, then it was slowly pressurized by hand utilizing a pipet bulb. The 
ink formulation was investigated by preparing three PA Inks, which will be denoted as PA Ink 1, 
2, and 3. PA Ink 1 was prepared by first dissolving 51.1 µL of EY stock, 307.5 µL DMSO, 13.1 
µL triethylamine (EtO3), and <0.01 mg nile red (NR) in a 1-dram vial. Next, 782 µL of purified 
TMPTA was added to the 1-dram vial and vortexed vigorously for a few minutes to obtain a 
homogenous solution. PA Ink 2 was prepared in a similar way as PA Ink 1; however, 1803 µL of 
DMSO was added instead of 307.5 µL of DMSO. PA Ink 1-AA was also prepared in a similar 
way as PA Ink 1; however, 14.3 mg of ascorbic acid (AA) was added instead of EtO3. After ink 
preparation, a small aliquot was syringed into a 1-dram vial and illuminated with blue light to 
ensure the solution gelled. After the gelation check test, the remaining solution was syringed into 
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a Dimatix Materials Cartridge Model # DMC-11610/PN 2100201146, and the printer head was 
snapped into place. The cartridge was then placed into the Dimatix 2831 inkjet printer and the 
polyvinyl alcohol film (PVA) was placed on the 12" x 8" platform. Utilizing the printer software 
the droplets were programed for placement 254 microns apart from center to center. The printer 
cartridge temperature was set to 37 °C. The printing height from the substrate was set to 2000 
microns with a substrate height of 1000 microns. The waveform used to eject droplets is shown 
in Figure 7.  
 
Figure 7. Multistep pulse waveform with a maximum voltage of 12 V used to eject one set of 
droplets from the printer cartridge nozzles.  
 
Next, the printing was started and a desk lamp containing a sunlite® (80145/3W/B 3WE261506 
120V 60Hz 46mA) blue light bulb was held approximately one cm above the substrate and 
moved behind the printer head. Figure 8 shows the strength of the light source with distance as 
determined utilizing a radiometer.  
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Figure 8. Radiant flux for the visible light source (desk lamp containing a sunlite® (80145/3W/B 
3WE261506 120V 60Hz 46mA) blue light bulb) as a function of the distance from the radiometer. 
 
Once the printing was completed the PVA film was placed in a container lined with aluminum foil 
where illumination with visible light was continued for at least five minutes. The printed film was 
kept covered until use.  
2.4.1 Ink optimization via gel yield studies 
Gelation kinetics of potential photoreactive ink components were investigated utilizing 
gel yield studies. These experiments were started by first pipetting 10 µL of the ink solution onto 
a Teflon substrate. The droplet was then illuminated with blue light for different periods of time 
depending on the rate of reaction. After each time point the droplet was moved into a 1-dram vial 
containing water. If the droplet dispersed in the water then it was noted that no gel was formed. 
However, if part of the droplet stayed intact in the water, then it was rinsed with three mL 
aliquots of methanol, dichloromethane, methanol, water, and then soaked in water for 24 hours.  
This ensured that any unreacted starting material was removed.  
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The gel was then freeze dried and the yield was determined utilizing the following 
equation; 
Gel yield (%)= Wdry
Wsolid
 x 100      (3) 
where Wdry is the weight of the freeze-dried gel and Wsolid is the theoretical weight of solid in the 
initial droplet. 
2.4.2 Drug loading and encapsulation efficiency of a model hydrophobic drug 
Quantitation of a model hydrophobic drug ivermectin (875.1 g/mol) was determined 
utilizing high performance liquid chromatography (HPLC). The HPLC instrument was equipped 
with a Waters 2487 Dual λ Absorbance Detector, Waters binary HPLC pump, Waters In-line 
Degasser AF, Waters 600 Controller, Waters 717 plus Autosampler, and a reverse phase column 
(100 x 4.6 mm i.d., pore size 5 µm, Thermo Scientific). The mobile phase was composed of 
acetonitrile:water (75:25) and was degassed and filtered before use. An isocratic flow rate of 1 
mm/min was used at 35 °C to elute the drug and the absorbance was taken at 243 nm. Serial 
dilutions of ivermectin in acetonitrile:water (ACN:H2O 75:25) were prepared from 0.3 to 400 
µg/mL for the calibration curve. The prepared calibration curve had an R-squared value of 
0.99993. The encapsulation efficiency was determined for ivermectin loaded bulk hydrogels. 
This was done by first submerging the freshly gelled material in 100 mL of ACN:H2O (75:25) 
for a few seconds to wash the gel of non-encapsulated ivermectin. Next, the ivermectin was 
quantitated in an aliquot from the 100 mL solution to determine the amount of ivermectin that 
was not encapsulated within the hydrogel.  
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The encapsulation efficiency was determined utilizing the following equation; 
4?,			(?)74?	(6)4?,			(?) x	100%        (4) 
 
where Mi, (i) is the initial mass of ivermectin added to the ink solution and Mi, (w) is the mass of the 
washed ivermectin as determined by HPLC. 
2.4.3 Characterization 
 Fluorescent microscopy was used to investigate the microparticles on the poly(vinyl 
alcohol) PVA film and while suspended in water. The microparticles were irradiated with 543 nm 
light to induce fluorescence of the encapsulated nile red. Wide field fluorescent microscopy (Nikon 
AZ 100M) was used to investigate the droplet placement on the PVA film. Confocal imaging 
(Zeiss LSM 510) was used to investigate the microparticle size, microparticle shape, and 
distribution of the hydrophobic dye. For confocal analysis a piece of microparticle-laden PVA film 
was cut out and dissolved in a confocal dish containing water. The microparticles prepared from 
PA Ink 1 were sized using the 40x Plan-APOCHROMAT OIL lens and the Zeiss LSM Image 
Browser. The microparticles prepared from PA Ink 2 were sized using the 100x Plan-
APOCHROMAT OIL lens. The z-stack for PA Ink 1 microparticles was taken using a 63x Plan-
APOCHROMAT OIL lens. The z-stack for PA Ink 2 was taken using a 100x Plan-
APOCHROMAT OIL lens. 
Unconfined compression testing (Instron 5944) was used to evaluate the softness of 
hydrogels prepared from PA Ink 1 and 2. The bulk hydrogels were synthesized utilizing a 
syringe mold. Briefly, the top of a 6 mL syringe was cut off. Next, 1 mL of the solution was 
pipetted into the top of the syringe containing a syringe plunger. The top of the liquid was then 
illuminated for 20 minutes. The formed hydrogel was then popped out of the syringe with the 
syringe plunger and rinsed with 5 mL aliquots of water, methanol, dichloromethane, methanol, 
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and water. The hydrogel was then soaked in 225 mL of water for 24 hours and freeze-dried.  
Prior to compression testing the freeze-dried gels were soaked in deionized water for 24 hours. 
The compression head rate was set to 1 mm/min during testing. From the compression testing the 
stress versus strain curves were determined, and the compressive modulus was determined using 
the initial linear region from 0 to 2% for each sample. 
Swelling studies were used to evaluate the hydrophilicity of the hydrogels. The studies 
were performed by measuring the weight change of freeze-dried gels after soaking in deionized 
water at 37 °C. The bulk gels for PA Ink 1 and 2 were fabricated in a syringe mold. Briefly, the 
top of a 1 mL syringe was cut off. Next, 150 µL of liquid was pipetted into the top of the syringe 
containing the syringe plunger. The top of the liquid was then illuminated for 10 minutes. The 
formed hydrogel was then popped out of the syringe with the syringe plunger and rinsed with 3 
mL aliquots of water, methanol, dichloromethane, methanol, and water. Lastly, the hydrogel was 
soaked in 100 mL of water for 24 hours and freeze-dried. During testing the weight change was 
determined utilizing the following equation; 
4574848 	x	100       (5) 
where Ms is the mass of the swollen gel and Md is the mass of the dry gel. 
2.5 One-pot microparticles for controlled pulmonary drug delivery to eliminate malaria 
Two PA inks were formulated that would result in microparticles with extremely 
different network properties. This was done to efficiently determine the range of tunable 
degradation and release kinetics, and thereby allow us to efficiently determine the optimal ink 
formulation. Prior to ink preparation, eosin Y (EY) stock solution was prepared in dimethyl 
sulfoxide (DMSO) at 7.3 mg EY/mL DMSO and trimethylolpropane triacrylate (TMPTA) was 
purified by flowing monomer through a 5 ¾” glass pipet filled with 80% inhibitor remover. 
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Initially the TMPTA is allowed to flow from gravitational forces, then is slowly pressurized by 
hand utilizing a pipet bulb. Ivermectin was then weighed in an aluminum foil wrapped 1-dram 
vial after which the EY stock, triethylamine, TMPTA, and DMSO were added. The solution was 
then vortexed to ensure all components were completely dissolved. Next, the TMPTA was added 
and the solution was vortexed again to obtain a homogenous solution. Table 6 shows the 
composition of the formulated inks. 
Table 6. Formulated ink compositions for the fabrication of ivermectin loaded microparticles. 
Ink Eosin Y (mM) 
Triethylamine 
(mM) 
Trimethylpropyl 
triacrylate (mM) 
Ivermectin 
(mM) 
Ivermectin 
(wt%)* 
PA Ink 1-
IV13wt% 0.49 79.0 2445 126.7 13 
PA Ink 2-
IV13wt% 0.22 35.4 1096 57.2 13 
*wt% is based on final dry weight of microparticles. Abbreviation IV = ivermectin. 
 
2.5.1 In vitro release of ivermectin from bulk gels 
Ivermectin loaded bulk gels were prepared from PA Ink 1-IV13wt% and PA Ink 2-
IV13wt% ink compositions shown in Table 6. Gels were formed by pipetting 50 µL of ink 
solution into a cut-off 1 mL syringe. The blue light source, desk lamp containing a sunliteÒ 
(80145/3W/B 3WE261506 120V 60Hz 46mA), is rested on the syringe until complete gelation. 
The gels were then plunged from the syringe into a beaker containing 100 mL of ACN:H2O 
(75:25) for several seconds before being removed into an empty glass vial. 
The concentration of ivermectin was determined using high performance liquid 
chromatography (HPLC). The HPLC instrument utilized was an Agilent 1290 Infinity II LC 
System. The mobile phase was acetonitrile:water (75:25), and the method settings were set to 1 
mm/min eluent flow rate, 35 °C column temperature, and 243 nm absorbance measurements. The 
calibration curve was prepared using serial dilutions of ivermectin in acetonitrile:water (75:25) 
from 0.3 to 400 µg/mL. 
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 The in vitro ivermectin release from the bulk gels was performed in phosphate buffer 
saline (7.4 pH) containing 2 wt% tween 80 at 37 °C. Ivermectin solubility was determined as 
3000 mg/mL in the release media using HPLC. The ivermectin solubility results in a perfect sink 
concentration less than 300 µg/mL which is 10% of the maximum ivermectin solubility in the 
media. The release study was performed in a 50 mL centrifuge tube containing perfect sink 
media at 37 °C under gentle stirring at 100 rpm. Once the media was ready the gel was dropped 
into the release media and 550 µL aliquots of media were taken over time for HPLC analysis. 
The removed volume for each time point was then replaced with fresh media to maintain perfect 
sink conditions. 
2.5.2 In vitro degradation of bulk gels by reactive oxygen species 
In vitro degradation of bulk gels was investigated at conditions relevant to the deep lungs. 
The most likely mechanism of degradation for hydrophobic poly(acrylate) in the lungs is through 
oxidation by reactive oxygen species. Here the H2O2 concentration is expected to be in the 
micromolar to tens of micromolar range.31 The degradation study was performed at the higher 
end of this concentration range, 100 micromolar H2O2. Additionally, cobalt chloride was added 
in excess to generate free radical oxygen species that oxidize the esters in the poly(acrylate) 
backbone. The bulk gels for this experiment were prepared using PA Ink 1 and 2 in a similar way 
as the bulk gels for the release study. The degradation study was run in 45 mL of aqueous 100 
µM H2O2 1.53 µM CoCl2 that was gently stirring at 100 rpm. The degradation media was 
replaced twice weekly. For each measurement, the samples were removed from degradation 
media and soaked in 100 mL deionized water for three 30 minute periods, refreshing the 
deionized water each time. The gels were then freeze dried and weighed.  
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The gel weight loss over time was determined using the following equation; weight	loss	 % = GHG? 	x	100     (8) 
 
where Wt is the dry weight after some period of time and Wi is the initial dry weight. 
2.5.3 Characterization 
Scanning electron microscopy (JEOL JSM 6400) was utilized to determine the 
microparticle size. The samples were first mounted on a metal stub containing double sided tape. 
They were then carbon coated with 400 nm layers using a Ladd Research Industries Vacuum 
Evaporator (Burlington, VT) before SEM imaging. The microparticle size was determined from 
the SEM images after which the aerodynamic diameter was calculated using the following 
equation; dJ = dK ρ        (9) 
where da is the aerodynamic diameter, dg is the geometric diameter, and r is the bulk density. 
Ink gelation kinetics were investigated using gel yield studies. First, 10 µL of ink solution 
was pipetted onto a Teflon substrate. Next, the droplet was illuminated with a blue light source 
(desk lamp containing a sunliteÒ 80145/3W/B 3WE261506 120V 60Hz 46mA) for different 
periods of time depending on the rate of reaction. After the specified time period the droplet was 
physically moved using a spatula into a 1-dram vial containing approximately 1 mL of water. If 
the droplet remained intact then it was considered that the gel was formed. If the gel fell apart 
and dispersed in the water then the gel was considered to not have formed. The water was then 
removed and the gels were washed with aliquots of methanol, dichloromethane, methanol, and 
water. The gels were then soaked in water for 24 hours and freeze-dried.  
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The gel yield was calculated using the following equation; Gel	yield = G89:G5OP?8 x	100      (11) 
 
where Wdry is the weight of the freeze-dried gel and Wsolid is the theoretical weight of solid in the 
initial droplet. 
 Rheometry (TA Instruments) was used to determine the viscosity of inks. A 40 mm plate 
geometry was used with a gap of 500 nm. The test type was a steady state flow with a 5% 
tolerance and a 1 minute max point time at 30 ºC. The shear rate was ramped from 400 1/s to 600 
1/s linearly with 10 sample points each with a 5 second sample period. 
2.5.4 Microparticle fabrication using piezoelectric inkjet printing 
The microparticles were fabricated using a Dimatix materials printer (DMP-2850) with a 
Dimatix Materials Cartridge Model #DMC-11610/PN 2100201146. In a general procedure, the 
prepared ink was first injected into the cartridge using a glass pipet. The 16 nozzle printer head 
was then snapped to the cartridge and the assembled cartridge was inserted into the printer. The 
printer settings were then selected in the Dimatix software. The waveform selected was a 
multipulse waveform set to a maximum voltage of 12 V (see Figure 7). The nozzle temperature 
was set to 30 °C, the print speed to 1 kHz, the printed droplet spacing to 125 microns, the 
substrate height was set to 1000 microns, and the printing height above the substrate was set to 
2000 microns. A 220 mm x 160 mm polyvinyl alcohol film was then placed onto the printing 
area and the printing was commenced. During printing the printer head was followed with a desk 
lamp containing a sunlite (80145/3W/B 3WE261506 120V 60 Hz 46 mA) blue light bulb that 
was held approximately one cm above the substrate. See Figure 8 for the strength of the light 
source with distance. After printing was complete, the light was illuminated on the printed 
substrate for another five minutes. The microparticles were then removed from the PVA film by 
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dissolving the film at a PVA concentration of approximately 6.7 mg PVA/mL D.I water in a 50 
mL conical then spinning down at 7830 rpm for 5 minutes. The supernatant was then removed 
and the microparticles were spun down again, re-suspended with 1.5 mL of deionized water, and 
pipetted into a “stock conical”. Once all microparticles were removed from the PVA film, the 
stock conical was spun down at 7830 rpm for 20 minutes and freeze-dried. 
2.5.5 In vitro drug efficacy of ivermectin and ivermectin loaded microparticles 
Chinese hamster ovary cells (CHO-K1, ATCCÒ CCL-61ä) were purchased from 
American Type Culture Collection (ATCCÒ) and growth media was prepared by adding 10% FBS 
(Gibco, USA) and 5% penicillin/streptomycin to Kaighn’s modification of Ham’s F-12. Cells were 
grown in tissue culture flasks (75 cm2) and maintained under 5% CO2 atmosphere at 37 °C in 
complete growth media. After the cells reached approximately 80% confluency they were split and 
seeded at a 1:5 to 1:10 ratio.  
Standard MTT (Invitrogenä Molecular Probesä Vybrantä) assays were used to 
determine the cell cytotoxicity of poly(acrylate) microparticles, pure ivermectin, and ivermectin 
loaded poly(acrylate) microparticles. CHO cells were used as model mammalian cells as done 
previously for ivermectin.32 The MTT experiments were done as follows. The CHO cells were 
first harvested from confluent cultures by trypsinization. The concentration of cells in the 
suspension was then determined by counting the live cells in a 1:1 mixture of cell 
suspension:tryphan blue using a hemocytometer. The stock cell suspension was then adjusted to 
50,000 cells/mL with complete media. The suspension (200 µL) was then pipetted to wells in a 
96 well plate and incubated for 3 to 4 hours. After the cells were attached, the media was 
replaced with sample solutions suspended in complete media and incubated for 72 hours. The 
poly(acrylate) microparticles were prepared by fabricating bulk gels from PA Ink 1. The bulk 
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gels were then frozen using liquid nitrogen and crushed with a mortar and pestle. Suspensions of 
crushed microparticles were then prepared at 100, 10, 1, 0.1, and 0.01 µg/mL, and complete 
media was used as blanks for these samples. The pure ivermectin samples were prepared by 
preparing a stock solution of pure ivermectin in DMSO, then adding aliquots of this solution to 
complete media with 1 v/v% DMSO to obtain samples that had concentrations of 100, 10, 1, 0.1, 
and 0.01 µg/mL. Blanks composed of 1 v/v% DMSO were used for these samples. The 
ivermectin loaded poly(acrylate) microparticles were fabricated using the PA Ink 1-IV13wt% 
microparticle formulation. These samples were prepared by adding appropriate amounts of 
microparticles to complete media with 1 v/v% DMSO to obtain ivermectin concentrations of 
100, 10, 1, 0.1, and 0.01 µg/mL after complete drug release. After the 200 µL sample solutions 
were incubated with the cells for 72 hours the sample solution was removed and 200 µL of PBS 
was used to wash the wells. Next, 150 µL of MTT solution (500 µg/mL in complete media) was 
added, and the wells were incubated for 3 to 4 hours. A 125 µL portion of the MTT solution was 
then removed and 50 µL of DMSO was added to dissolve the formed formazan crystals. The 96 
well plate was then incubated at 37 °C for 10 minutes. After incubation, the sample absorbance 
at 540 nm was determined using a Tecan Infinite M200 PRO plate reader, and the cell viability 
was calculated using the following equation;  Cell	viability	 % = 	 RHRS 	x	100     (12) 
 
where At is the absorbance in A.U. for the test solution and Ac is the absorbance for the control 
solution. 
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2.5.6 In vitro transport of ivermectin from ivermectin loaded microparticles through a lung 
epithelial cell monolayer 
 
Rat epithelial lung cells (RL-65, ATCCÒ CRL-10354) were purchased from American 
Type Culture Collection (ATCCÒ). The cells were grown in tissue culture flasks (75 cm2) and 
maintained under 5% CO2 atmosphere at 37 °C in a serum free media, Gibcoä DMEM/F-12 
supplemented with 0.005 mg/mL insulin, 0.01 mg/mL human transferrin, 0.1 mM ethanolamine, 
0.1 mM phosphoethanolamine, 25 nM selenium, 500 nM hydrocortisone, 0.005 mM forskolin, and 
0.15 mg/mL bovine pituitary extract. The medium was exchanged three times weekly, and the cells 
were split 1:20 at 90% confluency. 
The apparent permeability of ivermectin through rat lung cell monolayers from 
ivermectin loaded microparticles was investigated using an in vitro lung model. The ivermectin 
loaded microparticles were fabricated using the PA Ink 1-IV13wt% formulation. TranswellÒ cell 
culture supports (1.13 cm2 polyester, 0.4 µm pore size) were seeded at a density of 1 x 105 
cells/cm2. The cells were allowed to attach for 24 hours before removing the media to develop 
cells at air-liquid (AL) interface conditions. The AL conditions were established by adding 0.5 
mL of media to the basolateral chamber only, which was replaced every other day. The media 
utilized for these studies was Gibcoä DMEM/F-12 supplemented with 10% v/v Gibcoä fetal 
bovine serum and 100 IU/mL penicillin and 100 ug/mL streptomycin antibiotic solution. Over 
time trans-epithelial electrical resistance (TEER) measurements were recorded using a MillicellÒ 
ERS-2 Volt-Ohm Meter with MERSSTX01 electrodes. Before taking resistance measurements 
0.5 and 1 mL of media were added to the apical and basolateral chambers respectively and 
allowed to equilibrate in the incubator for 20 minutes. The measured value was corrected for the 
resistance and surface area of the TranswellÒ filters. Additionally, before starting the transport 
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experiments the TEER value for the cell monolayers were taken and only cells with a monolayer 
resistance greater than 250 W cm2 were used as suggested by Hutter et al.33 
The transport experiment was performed by first equilibrating the cell monolayers with 
1.5 mL of PBS 2 wt% tween in the basolateral compartment and 0.51 mL of PBS 2 wt% tween 
in the apical chamber for one hour. The buffer solution in the basolateral chamber was then 
refreshed with 0.51 mL of sample solution. The same initial concentration was used for each 
sample solution which was chosen to ensure perfect sink conditions were maintained. After 
certain periods of time 550 µL samples were taken from the basolateral chamber for HPLC 
analysis. The removed media was replaced with fresh buffer to ensure perfect sink conditions 
were maintained. Using the transport profile the apparent permeability coefficients were 
determined as done by Lang et al.34 using the following equation PJUU = V[X]VZ [[ \]^_          (13) 
where Papp is the apparent permeability coefficient, (d[I]/dt)ss is the change of concentration with 
time across the transwell filter, A is the surface area of the transwell filter, C0 is the initial 
amount of drug in the apical compartment, and V is the volume of the receiver compartment. 
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CHAPTER 3 
3. RESULTS AND DISCUSSION 
 
3.1 Novel functionalized copolymers for microparticle fabrication 
 
3.1.1 Hydrophobic linear poly(carbonate) copolymers 
 
Hydrophobic functionalized linear poly(carbonate) copolymers were fabricated as one of 
the network precursor copolymer building blocks for microparticle fabrication. Poly(carbonate)s 
are advantageous over other copolymers due to their degradation products being less acidic than 
other copolymers used for drug delivery such as poly(ester)s. As done previously by our group the 
poly(carbonate) copolymers were synthesized through the copolymerization of methyl ethyl 
carbonate and methyl allyl carbonate using ring opening metathesis polymerization with Sn(OTf)2 
as the catalyst.35 In this work, the copolymers were synthesized to contain 20% of allyl 
incorporation which can react with dithiol crosslinkers through a thiolene “click” reaction. To 
ensure extended release of drug was achieved the copolymers were synthesized with a mean 
average molecular weight of 4,000 g/mol which should result in small mesh sizes. After synthesis, 
the mean average molecular weight was determined using 1H-NMR. Figure 9 shows a 
representative 1H-NMR spectrum for the poly(carbonate) copolymer. 
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Figure 9. 1H-NMR for the methyl ethyl carbonate:methyl allyl carbonate (MEC:MAC) copolymer 
in CDCl3 (* = protons from terminal unit on polymer). d: 5.91-5.85 (m, -OCH2CHCH2), 5.34-5.23 
(m, -OCH2CHCH2), 4.64-4.62 (m, -OCH2CHCH2), 4.0-4.15 (m, MAC and MEC, -OC(O)OCH2), 
1.30-1.22 (m, MAC and MEC, CH3; MEC, -OCH2CH3), 0.93-0.91 (d, 3-methyl-1-butanol, 
OCH2CH2CH(CH3)2). 
 
The mean average molecular weight was determined by first setting the doublet f at 0.9 ppm shown 
in Figure 9 to 2.0. Peaks i at 1.24 ppm and d at 6 ppm were then integrated. The mean average 
molecular weight was then calculated using the following equation; Ma = (([i]7(b∗[d]))d ∗ MEC	MG + d ∗ [MAC	MG]      (14) 
where MEC MW is the molecular weight of methyl ethyl carbonate (188.18 g/mol), MAC MW is 
the molecular weight of methyl allyl carbonate (200.19 g/mol), [i] is the integrated area for the i 
peak, and [f] is the integrated area for the f peak. The methyl ethyl carbonate percentage of 
incorporation was calculated using the following equation; 
MEC	 % = (([i]h(i∗[d]))j ∗ 4kl	4m4n 	x	100	    (15) 
where Mn is the mean average molecular weight calculated from equation (14). 
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The methyl allyl carbonate % of incorporation was calculated using the following equation; MAC	 % = 	 [o]∗[4Rl	4m]4n x	100     (16) 
where Mn is the mean average molecular weight calculated from equation (14). Mn values ranged 
from 4,000 to 4,300 g/mol with 20% MAC incorporation. 
3.1.2 Hydrophilic semibranched poly(glycidol) copolymers 
The second copolymer synthesized was opposite of character to the hydrophobic linear 
poly(carbonate) copolymer. This copolymer was a hydrophilic semibranched poly(glycidol) that 
was also synthesized to contain 20% of pendant allyls that can react with dithiol crosslinkers. 
These copolymers were synthesized through the copolymerization of glycidol (GLY) and allyl 
glycidol ether (AGE) using cationic polymerization with Sn(OTf)2 as the catalyst. This synthesis 
strategy was done previously in our lab for a homopolymerization of poly(glycidol).30 This 
polymerization was invented in our lab and is more advantageous over traditional methods to 
fabricate branched poly(glycidol) since it doesn’t use protection of hydroxyl groups and it is much 
more controlled. Traditionally without the protection of glycidol monomers hyperbranched 
structures occur with no degree of control over the branching through anionic polymerization 
under stringent water free conditions.36 In general, hyperbranched poly(glycidol)s have a degree 
of branching of 0.56 to 0.63 where a 0.0 degree of branching would be a linear poly(glycidol).   
Additionally, these copolymers overcome the limitations of conventional PEG equivalents 
due to their increased tunability. For example, PEG copolymers are typically only commercially 
available in high molecular weights which result in large mesh sizes and fast release rates. Whereas 
our poly(glycidol) copolymers were synthesized at small molecular weight to target smaller mesh 
sizes and slow release rates. The low copolymer molecular weight is also advantageous for its 
faster elimination after the microparticle structure degrades. Additionally, commercially available 
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PEG copolymers are not branched like the synthesized poly(glycidol) in this work. The branched 
nature of the poly(glycidol) copolymers results in a large amount of hydrophilic end groups which 
results in the copolymer having a high hydrophilicity. These properties make the copolymer water 
soluble and give it an ability to protectively solubilize biologicals which improves their biological 
half-life and circulation time.37 Additionally, the hydroxyl groups open the doors to graft 
molecules for specialized applications in drug delivery.38  
Inverse gated 13C-NMR was utilized to determine the degree of branching. Figure 10 shows 
a comparison of the GLY/AGE (80:20) copolymer and GLY homopolymer catalyzed with 
Sn(OTf)2. 
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Figure 10. Inverse gated 13C-NMR spectra of the; Sn(OTf)2 catalyzed AGE:GLY copolymers (a. 
full spectra and b. zoomed in spectra), 13C-NMR (150MHz, MeOD) δ: 136.31, 117.39, 81.37, 
79.81, 75.12, 73.88, 72.01-72.94, 70.42-71.17, 64.41, 62.53, 62.06, 27.99, 27.60 and the Sn(OTf)2 
catalyzed GLY homopolymers (c. zoomed out spectra), 13C-NMR (150MHz, MeOD4) δ: 81.33, 
79.75 73.84, 72.36, 70.90, 70.62, 64.32, 62.71. 
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The degree of branching was calculated for the AGE:GLY copolymer using the following equation Degree	of	branching = q∗rq∗rstu,vstu,istwxy      (17) 
where D, L1,3, L1,4 and LAGE are the integrated peaks corresponding to each repeat unit. Whereas 
the degree for the GLY homopolymer was calculated using the following equation Degree	of	branching = 	 q∗r(q∗rstu,vstu,i)     (18) 
The degree of branching for the AGE/GLY copolymer and GLY homopolymer were 0.21 
and 0.39 respectively which indicate semibranched structures and that the GLY homopolymer had 
a higher degree of branching than the AGE/GLY copolymer. The allyl group incorporation for the 
green AGE/GLY copolymers was determined using 1H-NMR. Figure 11 shows a representative 
1H-NMR spectrum for the copolymer in MeOD4. 
 
Figure 11. 1H-NMR for the AGE/GLY copolymer in MeOD4, δ:6.0-5.90 (m, –OCH2CHCH2), 
5.37–5.17 (m, –OCH2CHCH2) 3.97-3.42 (6H). 
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The allyl group incorporation was determined as follows. First, the number of GLY monomers per 
repeat unit were calculated using the following equation GLY	R. U. (#) =  	7	bb        (19) 
 
where [b] is the area of the peak integrated in Figure 11. The allyl group incorporation was then 
calculated using the following equation AGE	 % = [J][J]st	.. # 	x	100	     (20) 
 
where [a] is the area of the peak integrated in Figure 11. The molecular weight of the repeat unit 
(R.U.) was then calculated using the following equation 
 R. U. g/mol = AGE	MG + t	(%)Rk	(%) ∗ GLY	MG     (21) 
 
where AGE Mw and GLY Mw are the molecular weights of the monomers which are 114 g/mol 
and 74 g/mol respectively. Incorporation of AGE was 20% as determined using 1H-NMR. 
 The poly(glycidol) was also synthesized using a “green synthesis”. The advantage of this 
synthesis is that it is run in water without the Sn(OTf)2 catalyst, and a higher degree of control is 
afforded. For example, the PDI for the Sn(OTf)2 poly(glycidol) was 1.6 whereas the green 
synthesis results in a PDI of 1.1. The temperature for the homo GLY polymerization was 
optimized to ensure the best yield and purity. We found that the polymerization at 60 °C resulted 
in a very low yield, 100 °C resulted in impurities present, and 80 °C to be the optimal reaction 
temperature in terms of yield and purity. In a similar way as reported for the Sn(OTf)2 
synthesized GLY/AGE and GLY copolymers, the degree of branching was also determined for 
the green synthesized GLY/AGE and GLY copolymers using inverse gated 13C NMR. Figure 12 
shows representative 13C-NMR spectra for the green synthesized GLY/AGE (70:30) copolymer 
and GLY homopolymer. 
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Figure 12. Inverse gated 13C-NMR spectra for the; green synthesized AGE:GLY copolymer (a. 
full spectra and b. zoomed in spectra), 13C-NMR (150MHz, MeOD4) δ: 136.31, 117.39, 81.37, 
79.81, 75.12, 73.88, 72.01-72.94, 70.42-71.17, 64.41, 62.53, 62.06, 27.99, 27.60; green 
synthesized GLY homopolymer (c. zoomed out spectra), 13C-NMR (150MHz, MeOD4) δ: 81.33, 
79.75 73.84, 72.36, 70.90, 70.62, 64.32, 62.71. 
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The degrees of branching were calculated using equations (17) and (18) for the green synthesized 
AGE/GLY copolymer and GLY homopolymer which were determined as 0.21 and 0.25 
respectively. These values indicate semibranched structures, with the GLY homopolymer having 
a higher degree of branching than the AGEGLY copolymer. MALDI was utilized to determine the 
Mn and Mw of the green synthesized homopolymer. In order to determine the molecular weight 
of the polymer species, direct integration of the obtained peaks was performed. This allowed for 
the calculation of Mn and Mw values, which also allowed for the determination of PDI. Shown in 
Figure 13 representative peaks are identified and assigned to a structural unit of the poly(glycidol). 
Mx* + M = 1 polymer chains were initiated by water and correspond to monomer units illustrated. 
 
Figure 13. MALDI spectra of the green synthesized poly(glycidol) homopolymer.  
 
The Mn was determined from the MALDI spectra as 925 g/mol and the Mw was determined as 
1041 g/mol which results in a PDI of 1.1. The allyl incorporation for the green synthesized 
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AGE/GLY copolymer was determined as 11% using the integrated 1H-NMR spectrum and 
equation (20). When we targeted for a higher incorporation of AGE into the copolymer using a 
50/50 feed ratio of the monomers, the polymerization achieved very low yield. 
3.2 Microparticle fabrication using photoreactive copolymer inks and piezoelectric ink jet 
printing 
 The goal for the photoreactive inks was to develop a minimal amount of inks that can be 
utilized to fabricate microparticles with a wide range of properties important in drug delivery. This 
results in one comprehensive technology to fabricate microparticles for a wide range of drug 
delivery applications. This goal was partly accomplished by developing a small set of diverse 
tunable copolymers and strategic selection of other ink components. The developed inks allow for 
tunability of properties important in drug delivery such as the release kinetics, type of drug loading 
(synthetic hydrophobic, synthetic hydrophilic, and/or biologicals), and microparticle circulation 
time. In general, the inks allowed for the preparation of microparticles with tunable release kinetics 
through tuning microparticle network density, the type of drug loading through the final 
microparticle hydrophilic character, and the circulation time through the microparticle softness. 
3.2.1 Poly(carbonate) microparticles 
 PC Ink 1 was utilized to fabricate poly(carbonate) microparticles. The target properties for 
these microparticles were high to medium network density, low hydrophilicity, and high to 
medium softness. Figure 14 shows a scheme that contains the chemical structures for the ink 
components and the proposed chemical structure for the crosslinked microparticles.  
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Figure 14. Chemical structures for the PC ink components and the crosslinked microparticle 
network. 
 
The high to medium network density comes from the incorporation of 10 to 40% of reactive 
monomers in the copolymer and the incorporation of a crosslinker that only has 2 repeat units. The 
low hydrophilicity comes from the fact that there are no hydrophilic functional groups in the 
copolymer. The high to medium softness comes from the 10 to 40% of reactive monomer 
incorporation and the crosslinker that only has 2 repeat units. The crosslinking for this ink occurs 
through a thiolene “click” reaction. The reason for this name is that it occurs rapidly, and is also 
very efficient.39 These fast gelation kinetics are important in printing applications for high-
throughput microparticle production. Furthermore, 2,2-Dimethoxy-2-phenylacetophenone 
(DMPA) is the initiator incorporated which is activated via UV light, and nile red is incorporated 
to enable visualization of the microparticles after printing. Dimethyl sulfoxide is used because it 
is able to dissolve chemically diverse species. Although this ink is optimal for fabrication of 
hydrophobic microparticles that are optimal for an extended release of hydrophobic drug, a 
hydrophilic drug could also be incorporated allowing for dual drug loading. 
  Confocal microscopy was utilized to image the distribution of the fluorescent molecule 
throughout the microparticle, as well as to investigate the shape and size precision of the fabricated 
microparticles. Figure 15a and 15b shows a still image and a z-stack of the microparticles floating 
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in water respectively. The z-stack is a collection of several images that start at the bottom of the 
microparticles and move to the top of the microparticles along the z axis at a constant x and y 
location. Utilizing the software for the microscope, the microparticle size was determined 
as 10.6 ± 0.5 µm, resulting in a low CV of 5%. Furthermore, as shown in Figures 15a and 
15b the nile red has good uniformity throughout the microparticles and the microparticles are 
spherical.  
  
Figure 15. PC Ink; a. confocal image of microparticles floating in water (scale bar = 10 µm) and 
b. confocal z-stack images of microparticles floating in water (scale bar = 10 µm). 
 
3.2.2 Poly(glycidol) microparticles 
PG Ink 2 was utilized to fabricate poly(glycidol) microparticles. The target properties for 
these microparticles were medium to low network density, high hydrophilicity, and high to 
medium softness. Figure 16 shows a scheme that contains the chemical structures and the proposed 
structure for the crosslinked microparticles. 
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Figure 16. Chemical structures for the PG ink components and the crosslinked microparticle 
network. 
 
The medium to low network density comes from the incorporation of 10 to 40% of reactive 
monomers in the copolymer and the incorporation of a crosslinker that has 20 repeat units, 10 
times more repeat units than the poly(carbonate) ink crosslinker. The high hydrophilicity comes 
from the high number of hydrophilic end groups on the semibranched copolymer. The high to 
medium softness comes from the 10 to 40% of reactive monomer incorporation and the crosslinker 
that has 20 repeat units. The crosslinking for this ink also occurs through the thiolene “click” 
reaction. However, the solvent used in this ink is water. Additionally, the poly(glycidol) copolymer 
can be prepared through a green synthesis. Therefore, from copolymer preparation to the final 
formulation this ink has the ability to be completely green. This feature makes the ink attractive 
for the incorporation of biological therapeutics. However, due to the change in solvent, VA-044 
and Sulfo-Cy3 are incorporated as the initiator and the fluorescent dye respectively. 
As stated previously confocal imaging was utilized to investigate the distribution of the 
fluorescent molecule throughout the microparticle, as well as to investigate the shape and size 
precision of the fabricated microparticles. Figure 17a and 17b shows a still image and a z-stack of 
the microparticles floating in water respectively. Utilizing the software for the microscope, the 
microparticle size was determined as 2.4 ± 0.2 µm, resulting in a low CV of 8%. 
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Furthermore, as shown in Figure 17a and 17b the dye is homogenously distributed throughout the 
microparticles and the microparticles are spherical. 
  
Figure 17. PG Ink; a. confocal image of microparticles floating in water (scale bar = 2 µm) and b. 
confocal z-stack images of microparticles flowing in water. 
 
3.2.3 Poly(carbonate)-poly(glycidol) microparticles 
PC:PG (70:30) Ink was utilized to fabricate poly(carbonate)-poly(glycidol) microparticles. 
The target properties for these microparticles were high to low network density, intermediate 
hydrophilicity, and high to low softness. Figure 18 shows a scheme that contains the chemical 
structures and the proposed crosslinked structure. 
 
Figure 18. Chemical structures for the PC:PG (70:30) ink components and the crosslinked 
microparticle network. 
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The high to low network density comes from the incorporation of 10 to 40% of reactive monomers 
in the copolymer and the incorporation of a crosslinker that has 2 repeat units. However, a 
crosslinker of 20 repeat units could also be incorporated to expand the degree of tunability. The 
intermediate hydrophilicity comes from the incorporation of both hydrophilic and hydrophobic 
copolymers. The high to low softness comes from the 10 to 40% of reactive monomer 
incorporation and the utilization of a crosslinker that has 2 or 20 repeat units. The crosslinking for 
this ink also occurs through the thiolene “click” reaction. However, the solvent used in this ink is 
dimethyl sulfoxide. As stated previously dimethyl sulfoxide is important as the solvent for this ink 
because it can also dissolve diverse chemical species such as the incorporated hydrophilic and 
hydrophobic copolymers. Lastly, DMPA and coumarin-30 are incorporated as the initiator and dye 
respectively. 
As stated previously confocal imaging was utilized to investigate the distribution of the 
fluorescent molecule throughout the microparticle, as well as to investigate the shape and size 
precision of the fabricated microparticles. Figure 19a and 19b shows a still image and a z-stack of 
microparticles floating in water respectively. Utilizing the software for the microscope, the 
microparticle size was determined as 13.3 ± 1.2 µm, resulting in a low CV of 9%. 
Furthermore, as shown in Figure 19a and 19b the dye is homogenously distributed throughout the 
microparticles and the microparticles are spherical. 
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Figure 19. PC:PG (70:30) Ink; a. confocal image of microparticles floating in water (scale bar = 
10 µm), and b. confocal z-stack images of microparticles floating in water. 
 
3.2.4 Effect of copolymer molecular weight on gelation kinetics 
The effect of copolymer molecular weight on the gelation kinetics was investigated. The 
gelation kinetics are important in printing applications to increase high-throughput production 
through increasing gelation kinetics. Figure 20 shows the poly(carbonate) copolymer molecular 
weight versus the gelling time for PC Ink formulations with three different molecular weight 
copolymers. The results show that as the copolymer molecular weight increases the PC Ink 
gelation time also increases. This trend was also observed for a glutaraldehyde crosslinked 
chitosan gelation studies performed by other researchers.40 
 
	 56	
 
Figure 20. Effect of poly(carbonate) copolymer molecular weight on the PC Ink gelation kinetics; 
the molecular weight was varied and the copolymer concentration was kept constant. The 
poly(carbonate) copolymer contained 20% allyl incorporation. 
 
3.2.5 Effect of copolymer concentration on gelation kinetics 
 The effect of copolymer concentration on the gelation kinetics was investigated. The 
copolymer concentration on the gelation kinetics is also important to ensure fast gelation kinetics 
to maximize the high-throughput production microparticles via piezoelectric ink jet printing. 
Figure 21 shows the effect of poly(carbonate) copolymer concentration on the PC Ink gelation 
time. As shown in Figure 21 the gelation kinetics have an exponential decay relationship with 
increasing copolymer concentration. Given this trend the optimal copolymer concentration to 
obtain fast gelation kinetics and use the least amount of material would be at approximately 18 
wt% of copolymer.  
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Figure 21. Effect of poly(carbonate) copolymer concentration on the PC Ink gelation kinetics; the 
concentration was varied and the copolymer molecular weight was kept constant. The 
poly(carbonate) copolymer contained 20% allyl incorporation. 
 
3.2.6 Tuning microparticle size through the printing waveform and ink dilution 
The volume of droplets ejected from a piezoelectric inkjet printing nozzle can be tuned by 
manipulating the nozzle size, temperature, and jetting waveform. Therefore, by tuning the droplet 
ejection volume, the final microparticle size can be tuned. Figure 22 shows an example of how the 
final microparticle size was tuned through the jetting waveform driving the droplet ejection. Figure 
22a shows the two-step waveform recommended by the manufacturer (40 V max) which results in 
microparticles that are approximately 18 microns in size (Figure 22b). Whereas Figure 22c shows 
a push-pull waveform (12 V max) that results in microparticles that are approximately 16 microns 
in size as shown in Figure 22d. 
	 58	
 
Figure 22. Microparticle size tuning by manipulating the jetting waveform; a. multipulse 
waveform (40 V max), b. 18 micron sized particle fabricated from the multipulse wavefrom (40 V 
max), c. push-pull waveform (12 V max), and d. 16 micron sized particle fabricated from the push-
pull waveform. 
 
We also discovered a way to tune the microparticle size through the ink copolymer 
concentration. We hypothesized that with a decrease in weight percent of copolymer solution, the 
solid amount in each ink droplet should decrease, which should then lead to a decrease in the size 
of the final crosslinked printed droplets. This hypothesis was investigated by decreasing the mass 
percent of the copolymer solution by 20% while keeping the volume constant. Figure 23 shows 
confocal microscope images of microparticles where a 20% reduction in copolymer concentration 
resulted in a 20% reduction in the microparticle size.  
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Figure 23. Microparticle size tuning through the ink copolymer concentration. A 20% reduction 
in copolymer concentration results in a 20% reduction in the microparticle size. 
 
3.2.7 Mechanical Studies 
 Unconfined compression tests were utilized to verify the predicted structure-property 
relationships for the softness of bulk hydrogels prepared from the developed inks. The softness is 
important for modulating the circulation time of microparticles. As reported by Merkel et al. a 30x 
increase in microparticle softness results in an 8x increase in microparticle circulation time.41 
Figure 24 shows the stress versus strain curve for bulk hydrogels prepared from each copolymer 
ink. As predicted the hydrogels fabricated from the PG Ink (semibranched poly(glycidol), 20 R.U. 
cross-linker) were the softest, the PC Ink (linear poly(carbonate), 2 R.U. cross-linker) hydrogels 
were the least soft, and the hydrogels fabricated from PC:PG (70:30) Ink (linear poly(carbonate) 
and semibranched poly(glycidol), 2 R.U.) resulted in a hydrogel that had intermediate softness.  
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Figure 24. Stress versus strain curve as determined using unconfined compression tests on bulk 
hydrogels; PC Ink (red circles), PG Ink (green circles), and PC:PG (70:30) Ink (blue circles). All 
data represent the mean of triplicate samples ± 1 standard deviation. 
 
3.2.8 Swelling Studies 
 Swelling studies were utilized to verify the predicted hydrophilicity for bulk gels fabricated 
from each copolymer ink. The swelling was quantified using the equilibrium swelling weight 
change which was determined as the point at which water stopped being absorbed and the weight 
stopped changing. The hydrophilicity is important for drug delivery applications because it directly 
effects the drug loading type and release profile. For example, hydrophobic microparticles are 
optimal for a high loading and extended release of hydrophobic drugs. Whereas hydrophilic 
microparticles are optimal for a high loading and extended release of hydrophilic drugs and 
biologicals. Figure 25 shows the equilibrium swelling weight change for gels prepared from each 
copolymer ink. The poly(carbonate) gels increased in weight by 1 ± 1% and as predicted were the 
most hydrophobic. The poly(glycidol) gels showed an increase in weight of 1112 ± 236% and were 
the most hydrophilic as predicted. The poly(carbonate):poly(glycidol) (70:30) gels as predicted 
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showed an intermediate weight change between the poly(carbonate) and the poly(glycidol), and 
had intermediate hydrophilicity between the poly(glycidol) and the poly(carbonate) gels. 
 
Figure 25. Swelling studies in deionized water at 37 ºC. Equilibrium weight change for bulk gels 
prepared from; PC Ink (red), PC:PG (70:30) Ink (blue), and PG Ink (green). All data represent the 
mean of triplicate samples ± 1 standard deviation.  
 
3.3 Microparticle fabrication using photoreactive monomer inks and piezoelectric ink jet 
printing  
 
 The photoreactive copolymer inks allow for the fabrication of microparticles with a wide 
range of properties for a wide range of drug delivery applications, except for cases where an 
extreme extended release is needed. The goal for the development of this new extended release 
ink, was to prepare microparticles with the highest crosslinking density which should result in 
the longest extended release of all four inks. We sought to accomplish this goal by formulating 
this ink with 100% of photoreactive monomers as the precursory network components. In 
general, there are two significant differences with this monomer ink than the copolymer inks. 
First, the microparticle networks are prepared from readily available acrylate monomers, 
whereas for the copolymer inks, monomer and copolymer synthesis is required. This results in 
the new ink components being all commercially available and in a one-pot microparticle 
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fabrication method. Second, the light source was switched from a UV light to a low-cost visible 
light source, a simple desk lamp.  Visible light is advantageous over UV light because it is not 
absorbed by biologicals and has an inherent lower energy.42 Additionally, to increase the scalable 
potential of the process the substrate was switched from a lab-prepared sacrificial poly(glycidol) 
coated glass slide to a commercially purchased water soluble poly(vinyl alcohol) film. This 
substrate further increases the simplicity of the method and allows for applications in 
personalized medicine. 
	 The target properties for these microparticles were high network density, low 
hydrophilicity, and low softness. Figure 26 shows the chemical structures and the proposed 
structure for the crosslinked microparticles. 
 
Figure 26. Chemical structures for the PA ink components and the crosslinked microparticle 
network. 
 
The high network density and low softness was obtained from the 100% incorporation of 
photoreactive monomers, trimethylolpropane triacrylate (TMPTA). The monomer TMPTA is 
interesting because it has three vinyl groups that participate in the free radical polymerization.43-
44 The more reactive functional groups there are on the monomer, the higher the probability of 
the reaction, the faster the reaction kinetics. As mentioned previously the fast gelation kinetics 
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are important for high-throughput production of microparticles. The low hydrophilicity is 
obtained from the hydrophobic monomers which contain no hydrophilic functional groups. The 
incorporated initiator is Eosin y, which is activated by visible light. Due to the inherently lower 
energy of visible light, a co-initiator trimethylamine must be incorporated to lower the activation 
energy of initiation. However, a low-cost light source such as a simple desk lamp with a 2 W 
blue light bulb can be used. In a similar way as the PC Ink, the solvent dimethyl sulfoxide is 
utilized to allow for the dissolution of the ink’s diverse chemical components such as the 
hydrophobic monomer trimethylolpropyl triacrylate and the hydrophilic initiator eosin y. Lastly, 
nile red was incorporated as a fluorescent dye. 
3.3.1 Monomer ink optimization through gel yield studies 
 
 The monomer ink compositions were optimized through gel yield studies. Table 7 shows 
the compositions of each ink investigated. The first monomer ink denoted as PA Ink 1-AA was 
composed of eosin Y (initiator), ascorbic acid (co-initiator), trimethylolpropane triacrylate 
(monomer), dimethyl sulfoxide (solvent), and nile red (dye).  
Table 7. Photoreactive monomer ink compositions investigated via gel yield studies. 
Inks Initiator (EQ) Co-initiator (EQ) Monomer (EQ) Solvent (v%) Dye 
PA Ink 1-AA EY (0.02) AA (2.8) TMPTA (99) DMSO (33) NR 
PA Ink 1 EY (0.02) EtO3 (3.2) TMPTA (99) DMSO (33) NR 
PA Ink 2 EY (0.02) EtO3 (3.2) TMPTA (99) DMSO (70) NR 
a.Trimethylolpropane triacrylate (TMPTA), ascorbic acid (AA), nile red (NR), dimethyl 
sulfoxide (DMSO), eosin Y (EY), and trimethylamine (EtO3).  
	
The amount of DMSO added to PA Ink 1-AA was determined by finding the minimum amount 
needed to solubilize all components. This minimal amount of solvent maximizes the monomer 
concentration which should increase the rate of gelation. Ascorbic acid was initially chosen as 
the co-initiator since it was reported to help initiation under oxygen rich conditions.45 However, 
as shown in Figure 27 the gel yield for PA Ink 1-AA was only 4 ± 1% after 5 minutes. Due to 
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this low yield we sought a more efficient co-initiator that could increase the equilibrium gel 
conversion. Previous studies have shown that the stronger reducing agent trimethylamine can 
efficiently co-initiate a visible light type-2 initiator such as Eosin Y.46-47 Figure 27 shows that the 
gelation of PA Ink 1 co-initiated by trimethylamine resulted in a more significant gel yield of 52 
± 2% after 5 minutes. Next, we determined the most dilute ink that still resulted in a rapid 5 
minute gelation. We determined this maximum dilution since in our previous paper we found 
that we could tune the microparticle size by reducing the concentration of the network 
precursors.48 The most dilute ink that maintained gelation after 5 minutes is denoted as PA Ink 2 
in Table 7. Figure 27 shows that PA Ink 2 resulted in approximately half the gel yield at 
equilibrium than PA Ink 1. This indicates that microparticles prepared from PA Ink 2 should be 
approximately half the size of particles prepared from PA Ink 1.  
 
Figure 27. Gel yield over time for different ink compositions; PA Ink 1-AA (grey triangles), PA 
Ink 1 (blue squares), and PA Ink 2 (orange circles). All data represent the mean of triplicate 
samples ± 1 standard deviation. 
 
3.3.2 Mechanical studies 
 
	 The compressive modulus of bulk hydrogels fabricated used PA Ink 1 and 2 were 
determined utilizing unconfined compression testing. Mechanical properties are important for 
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modulating microparticle circulation time. As reported by Merkel et al. a 30x increase in 
microparticle softness results in an 8x increase in microparticle circulation time.41 Figure 28a 
displays stress versus strain curves for bulk hydrogels prepared from PA Ink 1 and 2. The 
compressive modulus was determined utilizing the linear region of Figure 28a from 0 to 2% 
strain. Figure 28b shows that the compressive modulus for PA Ink 1 hydrogels was 113 ± 64 
kPa, whereas the modulus for the PA Ink 2 hydrogels was 25 ± 9 kPa.  
 
Figure 28. Mechanical compression data for bulk hydrogels; A) stress versus strain curves, PA 
Ink 1 hydrogels (blue squares) and PA Ink 2 hydrogels (orange circles), B) compressive modulus 
values, PA Ink 1 hydrogels (blue) and PA Ink 2 hydrogels (orange). All data represent the mean 
of quadruplicate samples ± 1 standard deviation. 
 
Interestingly, the PA Ink 1 hydrogels were similar to that of white blood cells, and the PA 
Ink 2 hydrogels were similar to red bloods cells.22 Microparticles with these mechanical 
properties have potential for unique biomedical applications, and would be optimal as 
vascular-targeted drug carriers.22 
3.3.3 Swelling studies 
The weight change of bulk freeze-dried gels in deionized water at 37 °C was investigated 
using swelling studies. The rate and capacity of gel weight increase (water uptake) is an 
indication of gel hydrophilicity which has a significant impact on the drug loading and release 
kinetics. Figure 29 shows the weight change of gels prepared from PA Ink 1 and 2. As shown in 
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Figure 29 the gel prepared from PA Ink 1 rapidly reached equilibrium within one minute and 
increased in weight by 7.8 ± 1.7%. Whereas the PA Ink 2 gel reached equilibrium within 15 
minutes and increased in weight by 37.2 ± 1.2%. In general, the limited gel water uptake for both 
gels indicate that they are hydrophobic and would be optimal for hydrophobic drug loading. 
Additionally, PA Ink 2 gels should release drugs at a faster rate than PA Ink 1 gels. 
 
Figure 29. Weight change of bulk gels after soaking in deionized water at 37 °C; gels prepared 
from PA Ink 1 (blue squares) and PA Ink 2 (orange circles). All data represent the mean of 
triplicate ± 1 standard deviation. 
 
3.3.4 Fabrication of one-pot crosslinked microparticles using inkjet printing 
Figure 30 shows an overview of the printing process for microparticles fabricated 
using the monomer based inks. First, the network precursors are printed onto the 
poly(vinyl alcohol) (PVA) film using a 2831 Dimatix materials printer. After droplet 
ejection onto the substrates they are immediately illuminated with blue light to initiate 
network crosslinking.  
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Figure 30. Illustration of the microparticle fabrication process. The chemical structures for the 
network precursors are eosin Y (initiator), trimethylamine (co-initiator), and trimethylolpropane 
triacrylate (monomer). The confocal image was taken of a microparticle fabricated using PA Ink 
1 floating in water. 
 
Shown in Figure 31a is a fluorescent microscope image of printed PA Ink 1 droplets on 
the PVA film. This image shows that the droplets were accurately and precisely ejected 
onto the substrate based on the programmed printing array. Next, the crosslinked 
microparticles were removed from the PVA substrate by dissolving the film in water. 
Confocal microscopy was then used to image the microparticles. Utilizing the software 
for the microscope, the PA Ink 1 microparticles were determined to be 14.4 ± 0.6 µm, 
resulting in a low CV of 4%. Furthermore, a z-stack confocal image of one microparticle, 
displayed in Figure 31B, indicates that the microparticle is spherical and the dye 
homogenously distributed throughout.  
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Figure 31. Confocal images of microparticles fabricated from PA Ink 1; a. wide field 
microscope image of microparticles on the water soluble poly(vinyl alcohol) film (scale bar = 
500 µm) and b. confocal z-stack images of one microparticle suspended in water (scale bar = 20 
µm). 
 
We also demonstrated the technologies ability to tune the microparticle size through 
microparticle fabrication with the dilute PA Ink 2. Facile microparticle size tuning is important 
because it directly effects the type of administration that can be used for delivery and release 
kinetics. PA Ink 2 resulted in the fabrication of microparticles that were 7.1 ± 0.5 µm (CV=7%) 
in size as shown in Figure 32. An image of a microparticle fabricated from PA Ink 1 was 
included for comparison. By reducing the monomer concentration by 56%, the microparticle size 
was also reduced by 56%. 
 
Figure 32. Confocal images of microparticles floating in water fabricated with; a. PA Ink 1 and 
b. PA Ink 2. The size of the microparticles were reduced by 56% by reducing the monomer 
concentration by 56%. 
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The microparticle sizes obtained for Ink 1 and 2 have shown promise for intracellular49-50, 
injection51, parenteral52, oral8, and inhalation8-9, 53 for applications such as vaccinations, 
brucellosis, human papillomavirus, diabetes, inflammation, and asthma respectively.	
3.3.5 Drug loading and encapsulation efficiency of a model hydrophobic drug 
The drug loading and encapsulation efficiency of a model hydrophobic drug ivermectin 
(875.1 g/mol) was determined in bulk hydrogels fabricated from PA Inks 1 and 2. Here we 
determined that the order of component dissolution was important when preparing the ink. The 
drug was first dissolved in DMSO, eosin Y, and triethylamine by vortexing for a few minutes, 
then sonicating for 30 minutes at 37 °C. Once the drug was completely dissolved, 
trimethlyolpropane triacrylate was added and vortexed for a few minutes to obtain a homogenous 
solution. The drug loading was limited by its solubility in DMSO. After complete dissolution, 
the ink was gelled by illuminating the sample with blue light. Utilizing HPLC UV-VIS the drug 
loading and encapsulation efficiency was determined as 32.3 ± 2.0% and 98.1 ± 0.6% for PA Ink 
1 and 29.7 ± 0.8 and 90.0 ± 2.5% for PA Ink 2 respectively. 
3.4 One-pot microparticles for controlled pulmonary drug delivery to eliminate malaria 
3.4.1 Ink formulation 
 
The long-term goal of this project is to eliminate malaria. This work is focused on 
achieving a smaller goal towards this greater goal, the development of the optimal microparticles 
for malaria elimination. The goals to fabricate these microparticles were to 1) maximize network 
density, to minimize release rate and decrease doses needed, 2) maximize drug loading for a 
hydrophobic drug to decrease material needed for delivery, and 3) obtain an aerodynamic 
particle diameter of about 1 to 2 microns for efficient particle distribution in the deep lungs4. The 
strategy to accomplish goal 1) was to form the microparticle network from the monomer network 
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precursor, trimethylpropyl triacrylate. This should result in a very high network density 
microparticle which will minimize the release rate of drug. Additionally, to demonstrate the 
tunability of release the network density was tuned through the monomer concentration. From 
our previous work, we determined that a decrease in the monomer concentration resulted in 
decreased gel density, which should result in a faster release. The plan to achieve goal 2) was to 
use the hydrophobic network precursors trimethylolpropyl triacrylate to form the network, which 
should maximize hydrophobic drug loading. As previously mentioned we are able to incorporate 
up to 32 wt% in bulk gels. However, since the viscosity of the ink increases with increasing 
ivermectin concentration as shown in Figure 33, we were limited to a loading that results in a 
final dry weight of ivermectin in the microparticles of 13.1 wt%.  
 
Figure 33. Viscosity of PA Ink 1 solutions containing different concentrations of ivermectin as 
determined using steady state flow rheometry measurements at 30 °C. 
 
This ivermectin concentration results in an ink with a viscosity of 15 cP, the maximum reported 
viscosity that still obtains good printability as reported by the printer’s manufacturer, Fujifilm 
Holdings America Corporation. Goal 3) was sought after by maximizing the ink viscosity to 
decrease the fluid volume ejected. In our previous work48, we determined that 2 micron size 
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particles were the smallest that we could obtain. Therefore, in this work, the viscosity was 
increased as much as possible while still maintaining good printability (15 cP), to minimize the 
fluid volume ejected. 
The ink formulation was completed by careful selection of a solvent and initiator. Eosin 
Y was selected as the initiator since it is initiated by blue light, an inherently low energy source. 
Furthermore, the light source used is cost-efficient, a simple desk lamp quipped with a 2 W blue 
light bulb. However, due to the inherently lower energy source used, a co-initiator triethylamine 
was incorporated to lower the activation energy of the eosin Y initiation. Lastly, the solvent 
selected was dimethyl sulfoxide (DMSO) which is advantageous for its ability to dissolve 
chemically diverse species such as the water-soluble eosin y and the hydrophobic drug 
ivermectin. 
3.4.2 In vitro release of ivermectin from bulk gels 
 
The in vitro ivermectin release kinetics was investigated using bulk gels fabricated from 
PA Ink 1-IV13wt% and PA Ink 2-IV13wt%. The studies were performed in perfect sink media at 
37 °C to ensure the drug media concentration did not influence the release profile. Figure 34 
shows that the release profile for the bulk gel prepared from Ink 1-IV13wt% had a small burst 
release of approximately 5% of ivermectin, after which there is a slow linear release for at least 
21 days. On the other hand, the Ink 2-IV13wt% bulk gel profile had a larger burst release of 
approximately 10% of ivermectin, followed by a slower release rate that decreases nonlinearly 
over approximately two weeks. Given the release profiles shown in Figure 34 and the target 
extended release application, the PA Ink 1-IV13wt% formulation is optimal. 
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Figure 34. In vitro ivermectin release profiles from bulk gels; PA Ink 1-IV13wt% bulk gels 
(orange squares) and PA Ink 2-IV13wt% bulk gels (blue circles). All data represent the mean of 
triplicate ± 1 standard deviation. 
 
3.4.3 In vitro degradation of bulk gels by reactive oxygen species 
The in vitro degradation of bulk gels fabricated from PA Ink 1 and PA Ink 2 was 
investigated at conditions relevant in the lung alveoli. In this location within the lungs the likely 
mechanism for poly(acrylate) degradation is by reactive oxygen species. The hydrogen peroxide 
concentration found in this location is expected to be in the micromolar to tens of micromolar 
range.31 Therefore, the degradation study was run at the higher end of the range, 100 micromolar. 
Additionally, cobalt chloride was added as a reducing agent to produce oxygen free radicals 
responsible for the oxidation of the poly(acrylate). Figure 35 shows that bulk gels fabricated 
from PA Ink 1 have a weight loss of 6% after 11 days. Whereas the bulk gels fabricated from PA 
Ink 2 have a much faster weight loss of 52% after 11 days. Therefore, there is a significant 
degree of degradation tunability obtained through changing the monomer concentration. 
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Figure 35. In vitro degradation of bulk gels fabricated using PA Ink 1 (orange squares) and PA 
Ink 2 (blue circles). The degradation media was composed of deionized water with 100 µM 
H2O2, 1.53 µM CoCl2 at 37 °C. All data represent the mean of triplicate ± 1 standard deviation. 
 
3.4.4 Ivermectin loaded microparticle fabrication 
 
Ivermectin loaded microparticles were fabricated from PA Ink 1-IV13wt% and PA Ink 2-
IV13wt%. Using the microparticle sizes as determined from SEM, the aerodynamic diameters 
were calculated using equation (9) as 1.6 ± 0.7 and 0.8 ± 0.2 microns for PA Ink 1-13wt% and 
PA Ink 2-IV13wt% respectively. The microparticles obtained from PA Ink 1-IV13wt% are 
almost exactly in the size range to obtain efficient distribution in the lung alveoli, 1-2 microns.4 
Additionally, the in vitro release profile for this ink also yielded the longest extended release of 
ivermectin, and is most desirable for the target application. 
3.4.5 In vitro drug efficacy of ivermectin and ivermectin loaded microparticles 
 
The in vitro drug efficacy of pure ivermectin and ivermectin loaded microparticles 
fabricated from PA Ink 1-IV13wt% was determined using three-day cell viability studies. The 
drug efficacy of pure ivermectin and PA Ink 1-IV13wt% microparticles was quantitated by 
determining the half maximal inhibitory concentration (IC50), the concentration where only 50% 
of the cells remain alive after the time of the study. Regression analysis on the data showed that 
	 74	
pure ivermectin had an IC50 value of 33.2 ± 7.7 µg/mL whereas the PA Ink 1-IV13wt% 
microparticles had an IC50 value of 6.1 ± 0.9 µg/mL. The IC50 values indicate that the 
bioavailability of ivermectin is increased when releasing from the microparticles. This is likely 
due to the pure ivermectin samples degrading in solution before it is absorbed by the cells. 
Whereas for the PA Ink 1-IV13wt% microparticles, the ivermectin is protected within the 
microparticle until released, where the small released amount is immediately absorbed by the 
cells. The results indicate that less ivermectin will need to be delivered to achieve the same 
plasma concentrations as pure ivermectin delivery. In addition to drug efficacy, the effect of 
poly(acrylate) (PA) microparticles on cell viability was also determined to investigate 
poly(acrylate) cytocompatibility. As shown in Figure 36 the PA microparticles did not have a 
significant effect on the cell viability. 
 
Figure 36. In vitro cell viability after 3 days of exposure to; pure ivermectin (purple triangles), 
PA Ink 1-IV13wt% microparticles (orange squares), and PA microparticles (green diamonds). 
All data represent the mean of triplicate ± 1 standard deviation. 
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3.4.6 In vitro transport of ivermectin from ivermectin loaded microparticles through a lung 
epithelial cell monolayer 
 
An in vitro lung model illustrated in Figure 37 was utilized to investigate the in vivo 
ivermectin transport from the interior lung to the systematic circulation. This was done by 
determining the apparent permeability of ivermectin and utilization of an accurate in vitro-in vivo 
correlation54  developed by Mathias et al. to predict the in vivo lung absorption profile. Mathias 
et al. quantitated the correlation accuracy by plotting predicted absorption values versus actual 
absorption values, which resulted in a linear plot with an R2 value of 0.97.54 
 
Figure 37. Illustration of the in vitro lung model utilized to investigate the in vivo ivermectin 
transport from the interior lung to the systematic circulation. 
 
Figure 38 shows the ivermectin transport from the PA Ink 1-IV13wt% microparticles, the 
optimal microparticles for the target application. The apparent permeability coefficient for the 
ivermectin transport through the cell monolayer was determined as 1.3 x10-6 ± 1.1 x 10-7 cm/s 
using equation (13) and the initial steady state ivermectin transport. 
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Figure 38. Ivermectin transport from PA Ink 1-IV13wt% microparticles through a rat lung 
epithelial cell monolayer. All data represent the mean of triplicate ± 1 standard deviation. 
 
The predicted lung absorption was calculated by first determining the absorption constant using; 
 log KJ = 0.811 log PR − 1.99     (22) 
 
where Ka is the absorption constant and PAPP is the apparent permeability. The predicted 
absorption was then determined using; 
 %	Absorbed = 	AJ 1 − e7       (23) 
 
where Amax is the maximum % absorbed and t is the time. Figure 38 shows the predicted 
ivermectin absorption over time in vivo. Ivermectin should have a linear absorption for up to 
about 10 days after which the release rate decreases nonlinearly. Given the achievement of the 
long 21 day extended release of ivermetin.  Upon successful mass drug inhalation administration 
of PA Ink 1-IV13wt% microparticles, malaria would have a significantly higher chance of being 
eliminated over administration of conventional pure ivermectin tablets due to increased patient 
compliance. 
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Figure 39. Predicted ivermectin absorption in rat lungs as determined using an in vitro-in vivo 
correlation.54 The predicted profile was calculated using apparent permeability data determined 
in triplicate ± 1 standard deviation. 
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CHAPTER 4 
4. CONCLUSIONS 
 In this work, we developed a comprehensive technology that can easily fabricate tunable 
microparticles at a high rate with low CV; and have the ability to encapsulate synthetic 
hydrophilic, synthetic hydrophobic, and/or biological drugs with high drug loading and 
encapsulation efficiency. This was accomplished by development of a small set of photoreactive 
copolymer and monomer inks that were utilized to fabricate microparticles with a wide range of 
softness, hydrophilicity, and network density. The two copolymer building blocks synthesized 
were a functionalized hydrophobic linear poly(carbonate) and hydrophilic semibranched 
poly(glycidol). Additionally, the semibranched poly(glycidol) was synthesized using a green 
synthesis. This resulted in the development of an ink that is completely green. The copolymers 
were functionalized with allyl groups that crosslink with dithiol crosslinkers through a thiolene 
“click” reaction after initiation by UV light. The monomer inks were formulated using a tri-
functionalized monomer, trimethylolpropane triacrylate, that crosslinked via free radical 
polymerization after initiation by visible light. To ensure facile microparticle collection 
hydrophilic microparticles were fabricated using Teflon substrates whereas hydrophobic 
microparticles were fabricated using a water soluble poly(vinyl alcohol) film or sacrificial 
polymer coating. Fabricated dye loaded microparticles were then analyzed using confocal 
microscopy which confirmed the microparticle’s spherical shape, uniformity of the dye 
distribution throughout the microparticles, and the high microparticle size precision. 
Additionally, we fabricated microparticles in a large size range from 1 to 18 microns at a high 
droplet production rate of 1 kHz. Furthermore, larger microparticle sizes would be easily 
obtainable with printer cartridges with larger nozzle diameters. The capability of the inks to 
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fabricate microparticles of a wide range of hydrophilicity and softness was verified using bulk 
swelling and unconfined compression tests respectively. The capability to tune the microparticle 
size traditionally through the jetting waveform was verified, and a new discovered method to 
tune the microparticle size through the network precursor concentration was presented. After 
property verification, the technology was utilized to engineer the optimal microparticles for a 
specific drug delivery application, malaria elimination. The prototype microparticles were then 
investigated using a series of in vitro tests to evaluate their success for malaria elimination via 
pulmonary drug delivery. The results from these experiments show promise that the 
microparticles should make a significant step towards malaria elimination, and also demonstrates 
the capability of the developed technology to fabricate the optimal microparticles for a target 
drug delivery application. 
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APPENDIX 
Tables summarizing the publications reviewed for Sections 1.1 through 1.4 
 
Table A1. Extracted data from 100+ publications mostly from 2010 to 2018 on microparticles 
prepared with single drug loading. Abbreviations; drug loading (DL), encapsulation efficiency 
(EE), average (A), standard deviation (SD), product yield (PY), reference (R), 
precipitation/physical entanglement (P), polymerization/covalent crosslinking (G), or ionic 
crosslinking (I). 
Method Matrix Drug Disease Treated 
Route of 
Admin. DL (%) 
EE 
(%) 
A ± SD 
(µm) R 
Emulsion-P PLGA Insulin Diabetes Inhalation 3±0.2 51±7 2.5±0.4 55 
Emulsion-
G PMAA 
Insulin 
(diffusion 
loading) 
Diabetes Oral  ~85 1 56 
Emulsion-
G 
poly(PEGDM
A:MMA) 
Insulin 
(diffusion 
loading) 
Diabetes Oral 1.87 82±6 25±3 57 
Spray 
drying-P Dextran-TMC Insulin Diabetes Inhalation 9 to 9.7 
90 to 
97 10±4 
9 
Supercritic
al fluid-P 
N-trimethyl 
chitosan 
microparticles 
Insulin Diabetes Inhalation 48 97 2±2 10 
Emulsion-P PLGA-HPβCD/insulin Insulin Diabetes Inhalation 1.4±0.4 
59±1
6 
26.2±1.
2 
58 
Inkjet-P PLGA Paclitaxel Cancer  10 100 NR 59 
Inkjet-G 
(poly(NIPAAm
-co-MAA)) 
and HDDA 
Fluorescein     23.42 ± 1.07 
60 
Emulsion-
G 
(P(NIPAM-co-
AA)) Trypsin   49.3±2  7±~3 
61 
Emulsion-
G p-NIPAM 
Horse radish 
peroxidase 
(diffusion 
loading) 
    1.762±.046 
62 
Emulsion-
G 
poly(acrylic 
acid-co-
acrylamide) 
Peptide 
(diffusion 
loading) 
    70 to 90 ± NR 
63 
Emulsion-
G 
oligoLA-PEO-
PPO-PEO-
oliogoLA 
Bovine 
serum 
albumin, 
insulin, 
hemoglobin 
  9.7, 7, 8.7 NR NR 64 
Emulsion-P PLGA Bovine insulin Diabetes   84±2 
84±25 
and 
41±14 
65 
Emulsion-P PLGA 
Inactivated 
polio 
vaccination 
Vaccine Injection  ~70±4 ~8±3 
51 
Emulsion-
G PEGMA 
Lysozyme ( 
diffusion 
loading) 
  63 100  NR 66 
Emulsion-P polyester amide Celecoxib 
Knee 
osteoarthrit
is 
Intra-
articular NR NR 45±35 
67 
Emulsion-P 
PEG-4-acr 
disulfydry 
peptide 
Nanoparticle
s   85.9  
1.9±2.7 
to 
68 
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(enzymatically 
degrdable) 
9.6±3.1 
SW 
  AF 591 IgG   2    
Microfluidi
cs Phospholipid Doxorubicin Cancer  NR 94 
50 - 
200 
69 
Emulsion-
I-P PLLA-alginate 
Metoclopra
mide Heartburn  13.2±0.5 
66.54
±2.23 
~200-
300 
(NR) 
12 
Emulsion-
G 
Peptide 
functionalized 
PEG 
Dexamethas
one 
Inflammati
on Inhalation 0.38 7.6 7.2±4.3 
8 
  Methylene blue   0.24 4.8 4.5±1.8  
  Horseradish peroxidase   1.87 37.4 7.5±3.9  
Spray 
drying-P 
Mannitol-
Lactose-
Trehalose 
siRNA 
loaded 
PLGA NP 
 Inhalation 0.0381±0.007   
70 
Spray 
drying-P Maltose 
Doxorubicin 
in 
nanoparticle
s 
Cancer Inhalation 3  3.45±1.99 
71 
Spray 
drying-P 
PLGA-DPPC-
PVA-Gelatin-
cholesterol 
Paclitaxel Cancer Inhalation 1.76 84.1  72 
Spray 
drying-P 
Mannitol, 
trehalose, 
dextran, L-
leucine 
Bacteriopha
ge virus-like 
particle 
Human 
papillomavi
rus 
Oral and 
parenteral  64 4.6±1.7  
52 
Spray 
drying-P  Lysozyme    
-25% 
activi
ty 
 73 
Spray 
drying-P 
PLGA-DPPC-
trimethylchitos
an 
Ropinirole 
hydrochlorid
e 
Parkinson's 
disease Nasal 1.90±0.03 
95.20
±1.43 
2.09±1.
01 
74 
Film-G 
(prepared 
film and 
crushed 
and sieved) 
poly(itaconic 
acid-co-N-
vinyl-2-
pyrrolione) 
Salmon 
calcitonin  Oral 4.5±0.5 
Diffu
sion 
loadi
ng 
45-150 75 
  Urokinase   1.9±0.1    
  Rituxan B cell destruction  2.4±1.5    
Microfluidi
cs-I 
HE800 
exopolysacchar
ide 
Bovine 
serum 
albumin 
    102±5 76 
Microfluidi
cs-G 
PEG-
maleimide 
(protease 
degradable) 
Peptide 
conjugated 
VEGF 
Vasculariza
tion 
Subcutane
ous 
injection 
  50±5 77 
Emulsion-
G 
Chitosan-
Gelatin-
thermoresponsi
ve PEG 
Folic acid   NR NR 1±1 78 
Microfluidi
cs-G PEG 
Basic 
fibroblast 
growth 
factor 
  NR 80 
42.4±8.
6 to 
142.1±2
5.6 
79 
  
DNA 
nanoparticle
s 
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Microfluidi
c-G 
Hydrazide-
aldehyde-
functionalized 
carbohydrates 
Bupivacaine Anesthesia    49 to 92 ± 4 
80 
Emulsion-
G 
PMMA-
EGDMA 
Monosodiu
m phosphate   3.1 95 95 
81 
Emulsion-P acetylated dextran HFG-f 
Myocardial 
infarction 
Intramyoc
ardial 1.1±0.2 86±9 
28.3±1.
5 
82 
Emulsion-P Polyketal-Drug conjugate Estradiol 
Inflammati
on  11.1±0.4 96.0 
10.3±3.
4 
83 
Emulsion-P 
Vanillyl 
alcohol-
containing 
copolyoxalate 
Dexamethas
one Asthma Inhalation 1 20 13±5 
53 
Cyclodextri
n-CaO3-P 
Cyclodextrin-
CaO3 
5-
fluorouracil   NR  5±NR 
84 
  Na-L-thyroxine   NR  2±NR  
Emulsion-P PEG-PBT Anti-VEGF Neovascular-AMD IVT 22.1 90 64±32 
6 
Emulsion-
G PEG 
Protein (post 
conjugation) Targeting    31±7 
85 
Spray 
drying-P-I Alginate rhBMP-2 
Bone 
regeneratio
n 
Scaffold 0.045 (NR) 45 5±5 
86 
Mineralizat
ion 
CaCO3/rGO-
TEPA Doxorubicin Cancer  7.9 94.7 3±1 
87 
Spray 
drying-P Chitosan 
β-
galactosidas
e 
GI disorder Oral   3.5±1.9 88 
Emulsion-P PLGA L7/L12 Brucellosis Intracellular 0.25 55.6 6±NR 
50 
Total 
Recirculati
on One 
Machine 
(Emulsion)
-P 
PLGA GDNF Parkinson's 
Unilateral 
injection 
to brain 
0.28 ± 
0.05 
70 ± 
12 28 ± 8 
89 
Emulsion-I Alginate 
Hydrocortiso
ne 
hemisuccinat
e 
Colon-IBD Oral 11.1 22 89.6 ± 1.0 
90 
Aerosolizat
ion-I Alginate 
Hydrocortiso
ne 
hemisuccinat
e 
Colon-IBD Oral 8.8 22 51.8 ± 1.9 
90 
Microfluidi
cs-P PLLA Paclitaxel Cancer  4.6 97 31 ± 1 
21 
Emulsion-P PLGA Paclitaxel Cancer  2.7 95 10 ± NR 
91 
Emulsion-P PLGA Paclitaxel Cancer  4.7 85 16 ± NR 
92 
Emulsion-I Alginate Paclitaxel Cancer  15.5 48 10 ± 3 93 
Electrohydr
odynamic 
atomization
-P 
PDLLA-PLLA Paclitaxel Cancer  1.6 45 14 ± 13 94 
Supercritic
al fluid 
technology
-P 
PEG-PLLA Paclitaxel Cancer IV 10.9±2.8 18.1 2.3 95 
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Supercritic
al fluid 
technology
-P 
PLLA Paclitaxel Cancer IV 14.3 62.7 1.6±1.2 19 
Microfluidi
cs-P PCL-PLA None N/A N/A N/A N/A 
26.5 ± 
0.7 
96 
Microfluidi
cs-P PLGA-b-PEG Paclitaxel Cancer  9.25 
92 ± 
2 
2.0 ± 
0.3 to 
4.5 ± 
0.3 
97 
Spray 
drying-P 
PLGA-L-
leucine or L-
aspartic acid 
Rifampicin Tuberculosis 
 
Inhalation 
19.2 ± 0.0 
to 12.3 ± 
0.0 
96.2 
± 0.6 
to 
70.5 
± 0.1 
5.9 ± 
3.8 to 
11.7 ± 
6.8 
18 
Spray 
drying-P Alginate VEGF N/A N/A 4.9 49 
3.9 ± 
NR 
98 
 
Spray 
drying-P 
Hyaluronic 
acid Budesonide 
 
N/A Inhalation 21.0 ± 0.3 
91.5 
± 1.5 
6.3 ± 
NR 
99 
Spray 
drying-P PLGA 
Methotrexat
e 
Cancer/aut
oimmune 
disease 
Inhalation 24.6 ± 0.4 91.3 ± 1.5 
5.6 ± 
0.7 
10
0 
Microfluidi
cs-P Phospholipids Doxorubicin Cancer N/A 30 
93 ± 
2 100 
20 
Microfludi
cs-P 
Polyacrylamide 
and polymethyl 
acrylate 
Sodium 
fluorescein Cancer N/A 1 30 
130 to 
155 
(<4.6% 
CV) 
14 
Spray 
drying - P 
N-
fumaroylated 
diketopiperazin
e 
azithromycin Pneumonia Inhalation 
23.9 ± 0.1, 
48.2 ± 
0.29 
NR NR 17 
 
 
Table A2. Compilation of different drugs encapsulated in microparticles with their 
corresponding chemical structure and size as determined through a literature search of 100+ 
publications mostly from 2010 to 2018. 
Drug Biological (Y/N) 
Hydrophobic 
or Hydrophilic 
Size 
(g/mol) 
Paclitaxel N Hydrophobic 854 
Azithromycin N Hydrophobic 749 
L7/L12 Y   
Hydrocortisone hemisuccinate N Hydrophilic 362 
Glial cell line-derived neurotrophic factor Y   
Insulin Y Hydrophilic 5,808 
Doxorubicin N Hydrophobic 544 
miR-34a Y   
Recombinant L7/L12 Y   
β-galactosidase Y  540,000 
rhBMP-2 Y  26,000 
Ovalbumin Y  45,000 
Bovine serum albumin Y  69,000 
Fluorescein N Hydrophilic 332 
Trypsin Y  23,300 
Horse radish peroxidase Y  44,000 
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Peptide Y   
Hemoglobin Y  16,000 
Inactivated polio vaccination    
Lysozyme Y  14,000 
Celecoxib N Hydrophobic 381 
AF 591 IgG Y  150,000 
Metoclopramide N Hydrophobic 300 
Methylene blue N Hydrophilic 320 
siRNA Y  13,000 
Bacteriophage virus-like particle    
Ropinirole hydrochloride N Hydrophilic 297 
Salmon calcitonin Y  3,454 
Urokinase Y  30,400 
Rituxan Y  35,000 
Basic fibroblast growth factor Y  18,000 
Vascular endothelial growth factor Y  38,000 
Bupivacaine N Hydrophilic 288 
Hepatocyte growth factor fragment Y   
Estradiol N Hydrophilic 272 
Dexamethasone N Hydrophobic 392 
5-fluorouracil N Hydrophilic 130 
Na-L-thyroxine N Hydrophilic 799 
Anti-vascular endothelial growth factor Y  150,000 
 
Table A3. Extracted data from 100+ publications mostly from 2010 to 2018 on microparticles 
prepared with dual drug loading. Abbreviations; drug loading (DL), encapsulation efficiency 
(EE), average (A), standard deviation (S), reference (R). 
Method Matrix Drug Disease Treated 
Route of 
Admin. DL (%) EE (%) 
AV ± S 
(µm) R 
Emulsion-P-
Por PLGA Doxorubicin Cancer Inhalation 0.773±0.03 77.2±0.9 46±21 
101 
  miR-34a   0.013±0.001 33.5±1.0   
Emulsion-P-
Por PLGA-PLLA Paclitaxel Cancer Inhalation 0.9±0.06 90.1±6.3 35±9 
102 
  Doxorubicin   9.1±0.7 45.3±3.3   
Emulsion-P-
Por PLGA Doxorubicin Cancer Inhalation 0.80±0.03 79.6±3.2 47±19 
103 
 PLGA miR-519c   0.023±0.001 29.0±1.3   
Emulsion + 
Microfluidic-
G 
NiPAm Nile red     140±10 104 
  DAPI       
Microfluidic-
P 
Hypromellose 
acetate 
succinate 
5FU Cancer Oral 0.0109 ± 0.00015  
27 ± 
0.8 
105 
  Curcumin Cancer Oral 0.009 ± 0.0013  
27 ± 
0.8  
Microfluidic-
G PEGDA nanoparticles     
2.8 ± 
0.2 to  
106 
  Acryloyl-RhB     
19.2 ± 
0.9  
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